



## The International Hormone Society

[www.intlhormonesociety.org](http://www.intlhormonesociety.org)

### References of Consensus 2 on Estrogen and Progesterone Treatment of Pre- and Postmenopausal Women

#### 1) Arguments against the use of non-bio-identical estrogens and non-bio-identical progestogens in women:

##### 1) The two major studies that have brought the present controversy on the use of female hormone replacement have shown that non-bio-identical hormones may risk of disease

**Women's Health Initiative (WHI) study: non-bio-identical hormones increase the cardiovascular and breast cancer risks**

1. Writing group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002; 288: 321-333

Facts:

*Premature stop of this large double-blind placebo-controlled study because of the increased risk of (RR) invasive breast cancer (1.26) et increased global risk index (1.15); The global risk would have remained negative at the end of the study, even if the results for prevention of cardiovascular disease would have inverted (low probability)*

Critics:

- The population of the study is not a representative population
  - *older patients (mean age: 63 years); patients have not been under H.R.T. before inclusion (period of no HRT between menopause and 63 yrs) => no real « primary prevention»:*
  - *not a healthy population: 2/3 of patients were overweight (BMI $\geq$ 25Kg/m<sup>2</sup>), 1/3 had morbid obesity (BMI $\geq$ 30Kg/m<sup>2</sup>); 35,7 % were hypertensive or treated for hypertension; 12,5 % were hypercholesterolemic; 4,4 % were diabetic or treated for diabetes*
  - *Toxic factor: about 50 % of the 8,500 women on HRT were smokers or had been smokers (Mueck AO, Seeger H. Smoking, estradiol metabolism and hormone replacement therapy. Arzneimittelforschung. 2003;53(1):1-11. Women's University Hospital, Tubingen, Germany. endo.meno@med.uni-tuebingen.de)*
  - *not a representative population of European patients*
- The medication is not a representative and safe female hormone replacement therapy (association of conjugated estrogens with medroxyprogesterone acetate)
  - *It is a popular medication in the USA, not in Europe*
  - *The type of hormones is not bio-identical*
  - *The route of administration for estrogens is the oral one. Results are possibly/probably not true for transdermal estrogens and for estradiol and progestogens of bio-identical structure (Stevenson JC, Whitehead MI. Hormone replacement therapy. BMJ. 2002 Jul 20;325(7356):113-4)*
- Not an easy study: (JAMA editorial)
  - *high drop-out rate: 42% of women have stopped the treatment during the study*
  - *10,7% of placebo group have began a H.R.T.*

**Million Women Study: > 99,97% of the hormones used where non-bio-identical hormones, which increased the breast cancer risk**

2. Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet*. 2003 Aug 9;362(9382):419-27

(Critics: Same critics as above; Additional:

- the study was not a double-blind placebo-controlled study, but an observational study based on patient's reports
- many of the participants had switched from one medication over to another during the study
- from the information that we have received, only about 300 of the one million women of the study had taken transdermal estradiol therapy, almost all on the estradiol patch, which may provide less constant estrogen levels (and of those only some 30 had taken the estradiol gel – that came out in the U.K. as official brand only two years after the start of the study and two years before its end)
- none of the women had taken progesterone (micronized, the bio-identical one), solely synthetic derivatives of progesterone were taken

**2) Other studies that show that estrogens with a NON BIO-IDENTICAL (foreign-to-the-human-body) structure, may adversely affect the body:**

**2-a) Absorption of non-bio-identical estrogens provides abnormal estrogens in the blood:**

**Treatments with equine estrogens (the Prempro of the WHI and Million Women studies) supply the blood with abnormal estrogens.** Equine estrogens contain estrone sulfate (53-61%), equilin sulfate (23-30%) equilenin, 17 a-dihydroequilin, 17 alpha-estradiol, 17 a-dihydroequilenin and numerous other horse estrogens

3. Morgan MR, Whittaker PG, Dean PD, Lenton EA, Sexton L, Cooke ID. Plasma equilin concentrations in an oophorectomized woman following ingestion of conjugated equine oestrogens (Premarin). *Eur J Clin Invest*. 1979 Dec;9(6):473-4
4. Bhavnani BR, Sarda IR, Woolever CA. Radioimmunoassay of plasma equilin and estrone in postmenopausal women after the administration of premarin. *J Clin Endocrinol Metab*. 1981 Apr;52(4):741-7
5. Utian WH, Katz M, Davey DA, Carr PJ. Effect of premenopausal castration and incremental dosages of conjugated equine estrogens on plasma follicle-stimulating hormone, luteinizing hormone, and estradiol. *Am J Obstet Gynecol*. 1978 Oct 1;132(3):297-302

**Treatments with ethinylestradiol (the Million women study):**

6. Goldzieher JW. Selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical implications. *Am J Obstet Gynecol*. 1990 Jul;163(1 Pt 2):318-22
7. Shenfield GM, Griffin JM. Clinical pharmacokinetics of contraceptive steroids. An update. *Clin Pharmacokinet*. 1991 Jan;20(1):15-37.

**2b) non-bio-identical hormones are almost always provided through the ORAL ROUTE, which is not the best route, nor a totally safe one:**

**2b-1) Treatments with oral estrogens provide imbalanced serum levels of estrogens and urinary levels of estrogen metabolites** (an abnormally high serum estrone level and an abnormal increase of urinary 16-alpha-hydroxy-estrone)

8. Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17-beta-estradiol: comparison with conventional oral estrogens used for hormone replacement. *Am J Obstet Gynecol*. 1985 Aug 15;152(8):1099-106
9. Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP, Judd HL. Biologic effects of transdermal estradiol. *N Engl J Med*. 1986 Jun 19;314(25):1615-20

**2b-2) Treatments with oral estrogens excessively increase the serum levels of the plasma binding proteins**

*How? Oral estrogens, after absorption in the intestinal tract, are transported to the liver where they accumulate. The liver produces under this "estrogen dominance" excessive amounts of hormone plasma binding proteins, resulting in high serum levels of the plasma binding proteins, which bind greater amount of various hormones in the serum, thus reducing the amount of hormones bioavailable for the target cells.*

10. Stumpf PG. Pharmacokinetics of estrogen. *Obstet Gynecol*. 1990 Apr;75(4 Suppl):9S-14S; discussion 15S-17S

## **2-b-3) Treatments with oral estrogens reduce the levels and activities of other hormones**

### ***Treatments with oral estrogens reduce serum IGF-1 levels and thus GH metabolic activity***

11. Wolthers T, Hoffman DM, Nugent AG, Duncan MW, Umpleby M, Ho KK. Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. *Am J Physiol Endocrinol. Metab.* 2001 Dec;281(6):E1191-6
12. Paasilta M, Karjalainen A, Kervinen K, Savolainen MJ, Heikkinen J, Backstrom AC, Kesaniemi YA. Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-I during oral and transdermal estrogen replacement therapy: relation to lipoprotein(a) levels. *Atherosclerosis.* 2000 Mar;149(1):157-62
13. Janssen YJ, Helmerhorst F, Frolich M, Roelfsema F. A switch from oral (2 mg/day) to transdermal (50 µg/day) 17beta-estradiol therapy increases serum insulin-like growth factor-I levels in recombinant human growth hormone (GH)-substituted women with GH deficiency. *J Clin Endocrinol Metab.* 2000 Jan;85(1):464-7
14. Cook DM, Ludlam WH, Cook MB. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. *J Clin Endocrinol Metab.* 1999 Nov;84(11):3956-60
15. Cano A, Castelo-Branco C, Tarin JJ. Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels. *Fertil Steril.* 1999 Feb;71(2):261-7
16. Bellantoni MF, Vittone J, Campfield AT, Bass KM, Harman SM, Blackman MR. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study. *J Clin Endocrinol Metab.* 1996 Aug;81(8):2848-53
17. Ho KK, Weissberger AJ. Impact of short-term estrogen administration on growth hormone secretion and action: distinct route-dependent effects on connective and bone tissue metabolism. *J Bone Miner Res.* 1992 Jul;7(7):821-7
18. Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. *J Clin Endocrinol Metab.* 1991 Feb;72(2):374-81

### ***Treatments with oral estrogens reduce the excretion of melatonin metabolites and thus melatonin activity***

19. Luboshitzky R, Shen-Orr Z, Herer P, Nave R. Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women with polycystic ovary syndrome: the effect of ethinyl estradiol-cyproterone acetate treatment. *Gynecol Endocrinol.* 2003 Dec;17(6):441-7

### ***Treatments with oral estrogens reduce serum free thyroid hormones, in particular serum free T3, and thus thyroid activity***

20. Rudorff KH, Herrmann J, Dieterich T, Kruskemper HL. Effect of estrogen upon thyroid metabolism. *Med Klin.* 1978 Aug 4;73(31):1109-13

### ***Treatments with oral estrogens reduce cortisol levels, and thus glucocorticoid activities***

21. Hammerstein J, Daume E, Simon A, Winkler UH, Schindler AE, Back DJ, Ward S, Neiss A. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol. *Contraception.* 1993 Mar;47(3):263-81

### ***Treatment with oral estrogens reduce free and total testosterone, DHT, DHEA, free cortisol, and thus androgen and glucocorticoid activities***

22. Coenen CM, Thomas CM, Borm GF, Rolland R. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives. *Int J Fertil Menopausal Stud.* 1995;40 Suppl 2:92-7
23. De Lignieres B, Basdevant A, Thomas G, Thalabard JC, Mercier-Bodard C, Conard J, Guyene TT, Mairon N, Corvol P, Guy-Grand B, et al. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. *J Clin Endocrinol Metab.* 1986 Mar;62(3):536-41

**2-c) Non-bio-identical hormones such as those of oral birth-control pills may not be better through the transdermal route (as transdermal patches):** They cause similar and on some points worse adverse effects than through the oral route.

- They increase similarly or even to a greater extent the levels of the plasma binding proteins
- They may cause similar or even to a greater extent reductions of hormone activities

24. Heger-Mahn D, Warlimont C, Faustmann T, Gerlinger C, Klipping C. Combined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers. *Eur J Contracept Reprod Health Care*. 2004 Sep;9(3):173-81))

**2c-1) The transdermal contraceptive patch** (Ortho Evra/Evra, 1 patch per week of 20 µg ethinyl estradiol with 150 µg norelgestromin, the active metabolite of the progestogen norgestimate, structurally related to 19-nortestosterone)

-

**The transdermal contraceptive patch provides higher levels of ethinylestradiol and SHBG, than the oral pill, but similar increase of on CBG**

25. Devineni D, Skee D, Vaccaro N, Massarella J, Janssens L, LaGuardia KD, Leung AT. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. *J Clin Pharmacol*. 2007 Apr;47(4):497-509.

**The transdermal contraceptive patch provides a higher level of SHBG and similar lowering effect on key serum androgen levels (DHEAs, free testosterone and androstenediol glucuronide) as oral contraceptive pills**

26. White T, Jain JK, Stanczyk FZ. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. *Am J Obstet Gynecol*. 2005 Jun;192(6):2055-9 (*patch versus oral contraceptive: 449% vs 274% increase in SHBG; -40 % vs -39% reduction of free testosterone, -26% versus - 32 % reduction in DHEA sulphate, and - 52 % versus -51% reduction in androstenediol glucuronide*)

**The transdermal contraceptive patch provides higher levels of SHBG and TBG and greater increase of CRP compared to the oral pill**

27. White T, Ozel B, Jain JK, Stanczyk FZ. Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins. *Contraception*. 2006 Oct;74(4):293-6

**The transdermal contraceptive patch causes a higher incidence of breast pain, dysmenorrhoea and application site reactions than the oral pill**

28. Radowicki S, Skorzewska K, Szlendak K. [Safety evaluation of a transdermal contraceptive system with an oral contraceptive] *Ginekol Pol*. 2005 Nov;76(11):884-9.

**The transdermal contraceptive patch causes a similar increase in risk of nonfatal venous thromboembolism for the contraceptive patch as for the oral contraceptive pills**

29. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. *Contraception*. 2006 Mar;73(3):223-8

**The transdermal contraceptive patch causes similar unfavourable lipid changes:** increases in total cholesterol and total triglycerides compared to the oral group

**2c-2) Other transdermal contraceptive patch:** ethinylestradiol/gestodene (.9 mg ethinylestradiol and 1.9 mg gestodene )

**2c-3) The vaginal contraceptive ring** (Nuvaring, 1 per 3 weeks; 2,7 mg of ethinylestradiol and 11,7 mg of etonogestrel, which supply 12 µg of etonogestrel and 15 µg of ethinylestradiol per day) supplies much less ethinylestradiol to the body

31. van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. *Contraception*. 2005 Sep;72(3):168-74.

**2d) Studies where oral and/or structurally non-bio identical estrogen treatments were associated with adverse effects on the cardiovascular system**

**Treatments with oral estrogens, including conjugated estrogens, disturb blood coagulation:**

***Treatments with oral estrogens increases factor VII activity***

35. Nozaki M, Ogata R, Koera K, Hashimoto K, Nakano H. Changes in coagulation factors and fibrinolytic components of postmenopausal women receiving continuous hormone replacement therapy. *Climacteric*. 1999 Jun;2(2):124-30

***Treatments with oral estrogens reduce tissue factor pathway inhibitor, a major inhibitor of the extrinsic coagulation pathway, and increase C-reactive protein, a component of the acute phase***

36. Luyer MD, Khosla S, Owen WG, Miller VM. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. *J Clin Endocrinol Metab*. 2001 Aug;86(8):3629-34

***Treatments with high doses of oral estrogens significantly increase serum alpha 1-antitrypsin and plasminogen levels***

37. Alkjaersig N, Fletcher AP, de Ziegler D, Steingold KA, Meldrum DR, Judd HL. Blood coagulation in postmenopausal women given estrogen treatment: comparison of transdermal and oral administration. *J Lab Clin Med*. 1988 Feb;111(2):224-8

***Treatments with oral estrogens significantly reduce antithrombin III and protein S activities***

38. Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. *Fertil Steril*. 2001 Jul;76(1):13-24
39. Bonduki CE, Lourenco DM, Baracat E, Haidar M, Noguti MA, da Motta EL, Lima GR. Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women. *Acta Obstet Gynecol Scand*. 1998 Mar;77(3):330-3

***Treatments with oral estrogens increase in matrix metalloproteinase-9 within the vessel wall: could digest and weaken fibrous caps of vulnerable plaques, thus provoking thrombosis***

40. Zanger D, Yang BK, Ardans J, Waclawiw MA, Csako G, Wahl LM, Cannon RO 3rd. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. *J Am Coll Cardiol*. 2000 Nov 15;36(6):1797-802

***Treatments with oral estrogens increase the risk of venous thromboembolism, especially during the first year***

41. Oger E, Scarabin PY. Assessment of the risk for venous thromboembolism among users of hormone replacement therapy. *Drugs Aging*. 1999 Jan;14(1):55-61

***Treatments with oral estrogens increase the risk of ischaemic stroke among postmenopausal women***

42. Oger E, Scarabin PY. Hormone replacement therapy in menopause and the risk of cerebrovascular accident. *Ann Endocrinol (Paris)*. 1999 Sep;60(3):232-41

***Treatments with oral estrogens and tibolone significantly increase serum CRP, while transdermal estradiol has no significant effect on serum CRP***

43. Prelevic GM, Kwong P, Byrne DJ, Jagroop IA, Ginsburg J, Mikhailidis DP. A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. *Fertil Steril*. 2002 May;77(5):945-51
44. Decensi A, Omodei U, Robertson C, Bonanni B, Guerrieri-Gonzaga A, Ramazzotto F, Johansson H, Mora S, Sandri MT, Cazzaniga M, Franchi M, Pecorelli S. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. *Circulation*. 2002 Sep 3;106(10):1224-8

**2e) Studies where treatments with structurally NON BIO-IDENTICAL estrogens were associated with an increased breast cancer risk**

**In vitro treatments with conjugated estrogens excessively stimulate epithelial proliferation in breast tissue, an effect worsened with the addition of medroxyprogesterone acetate (MPA)**

45. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. *J Clin Endocrinol Metab.* 1999 Dec;84(12):4559-65.

**Treatments with conjugated or other non-bio-identical estrogens increase the breast cancer risk**

46. Writing group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. *JAMA.* 2002; 288: 321-333
47. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet.* 2003 Aug 9;362(9382):419-27

**Studies with associations between hormone replacement treatments and increased risk of breast cancer**

**Studies where female hormone replacement treatments (generally with oral, non-bio-identical estrogens and synthetic progestogens) were associated with an increase in risk of breast cancer**

48. Persson I, Thurfjell E, Bergstrom R, Holmberg L. Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. *Int J Cancer* 1997 Sep 4;72(5):758-61
49. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. *JAMA* 2000 Jan 26;283(4):485-91
50. LeBlanc ES, Viscoli CM, Henrich JB. Postmenopausal estrogen replacement therapy is associated with adverse breast. *J Womens Health Gen Based Med* 1999 Jul-Aug;8(6):815-23
51. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. *J Natl Cancer Inst* 2000 Feb 16;92(4):328-32
52. Vessey MP. Effect of endogenous and exogenous hormones on breast cancer: epidemiology. *Verh Dtsch Ges Pathol* 1997;81:493-

**Studies that contest the validity of the above-mentioned studies**

53. Creasman WT. Is there an association between hormone replacement therapy and breast cancer? *J Womens Health* 1998 Dec;7(10):1231-46
54. Sitruk-Ware R. Hormone therapy of menopause and risk of breast cancer. *Polemics and Controversies. Presse Med* 1994 Jan 8-15;23(1):38-42
55. Franceschi S. Replacement therapy in menopause and risk for breast tumors. *Ann Ist Super Sanita* 1997;33(2):207-11

**Studies where female hormone replacement treatments (generally with oral, non-bio-identical estrogens) were associated with an increase in risk of breast cancer in women with familial breast cancer**

56. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, Berkelman RL. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. *JAMA* 1991 Apr 17;265(15):1985-90 (*higher risk of breast cancer in women with familial history of breast cancer if ever use of estrogen therapy; critic: other studies have shown that estrogen replacement did not induce a greater risk of breast cancer, but did reduce the overall mortality of women with familial history of breast cancer, see further*)

**3) Studies that show that progestogens with NON BIO-IDENTICAL structure may adversely affect the body:**

**3a) Studies where treatments with synthetic derivatives of progesterone (medroxyprogesterone acetate (MPA) and other progestogens) were associated with adverse effects on the cardiovascular system**

**Treatments with structurally modified progestogens block the beneficial effects of estrogens on the cardiovascular system (not the case with natural progesterone)**

57. Clarkson TB. Progestogens and cardiovascular disease. A critical review. *J Reprod Med.* 1999 Feb;44(2 Suppl):180-4
58. Lahdenpera S, Puolakka J, Pyorala T, Luotola H, Taskinen MR. Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles; comparison of transdermal and oral treatment regimens. *Atherosclerosis.* 1996 May;122(2):153-62
59. Wakatsuki A, Sagara Y. Effects of continuous medroxyprogesterone acetate on lipoprotein metabolism in postmenopausal women receiving estrogen. *Maturitas.* 1996 Aug;25(1):35-44

60. Cerquetani E, Leonardo F, Pagnotta P, Galetta P, Onorati D, Fini M, Rosano GM. Anti-ischemic effect of chronic oestrogen replacement therapy alone or in combination with medroxyprogesterone acetate in different replacement schemes. *Maturitas*. 2001 Sep 28;39(3):245-51
61. Duvernoy CS, Rattenhuber J, Seifert-Klauss V, Bengel F, Meyer C, Schwaiger M. Myocardial blood flow and flow reserve in response to short-term cyclical hormone replacement therapy in postmenopausal women. *J Gend Specif Med*. 2001;4(3):21-7,47
62. Williams JK, Hall J, Anthony MS, Register TC, Reis SE, Clarkson TB. A comparison of tibolone and hormone replacement therapy on coronary artery and myocardial function in ovariectomized atherosclerotic monkeys. *Menopause* 2002 Jan-Feb;9(1):41-51
63. Mueck AO, Seeger H, Wallwiener D. Medroxyprogesterone acetate versus norethisterone: effect on estradiol-induced changes of markers for endothelial function and atherosclerotic plaque characteristics in human female coronary endothelial cell cultures. *Menopause* 2002 Jul;9(4):273-281
64. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. *Circulation* 2001 Oct 9;104(15):1773-8
65. Register TC, Adams MR, Golden DL, Clarkson TB. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. *Arterioscler Thromb Vasc Biol* 1998 Jul;18(7):1164-71
66. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. *Nat Med* 1997 Mar;3(3):324-7
67. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. *Arterioscler Thromb Vasc Biol* 1997 Jan;17(1):217-21
68. Luckas MJ, Gleeve T, Biljan MM, Buckett WM, Aird IA, Drakeley A, Kingsland CR. The effect of progestagens on the carotid artery pulsatility index in postmenopausal women on oestrogen replacement therapy. *Eur J Obstet Gynecol Reprod Biol*. 1998 Feb;76(2):221-4
69. Gorodeski GI, Yang T, Levy MN, Goldfarb J, Utian WH. Modulation of coronary vascular resistance in female rabbits by estrogen and progesterone. *J Soc Gynecol Investig*. 1998 Jul-Aug;5(4):197-202

**Treatments with MPA have adverse effects on cardiovascular parameters, increasing the serum triglycerides**

70. Johnson JV, Davidson M, Archer D, Bachmann G. Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy. *Menopause*. 2002 Jan-Feb;9(1):16-22

**Treatments with MPA have adverse effect on coronary arteries, increasing arteriosclerosis (not the case with bio-identical progesterone)**

71. Miyagawa K, Vidgoff J, Hermsmeyer K. Ca<sup>2+</sup> release mechanism of primate drug-induced coronary vasospasm. *Am J Physiol*. 1997 Jun;272(6 Pt 2):H2645-54
72. Minshall RD, Stanczyk FZ, Miyagawa K, Uchida B, Axthelm M, Novy M, Hermsmeyer K. Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys. *J Clin Endocrinol Metab*. 1998 Feb;83(2):649-59
73. 3) Seeger H, Wallwiener D, Mueck AO. Effect of medroxyprogesterone acetate and norethisterone on serum-stimulated and estradiol-inhibited proliferation of human coronary artery smooth muscle cells. *Menopause*. 2001 Jan-Feb;8(1):5-9

**Treatments with MPA stimulate atheroma development (no effect of norethisterone)**

74. Seeger H, Wallwiener D, Mueck AO. Effect of medroxyprogesterone acetate and norethisterone on serum-stimulated and estradiol-inhibited proliferation of human coronary artery smooth muscle cells. *Menopause*. 2001 Jan-Feb;8(1):5-9
75. Sitruk-Ware R. Progestins and cardiovascular risk markers. *Steroids*. 2000 Oct-Nov;65(10-11):651-8

**Treatments with structurally modified progestogens may stimulate vasospasm of the coronary arteries (not the case with natural progesterone)**

76. Paris JM, Williams KJ, Hermsmeyer KR, Delansorne R. Nomegestrol acetate and vascular reactivity: nonhuman primate experiments. *Steroids*. 2000 Oct-Nov;65(10-11):621-7

**Progestins increase the risk of venous thrombo-embolic events, but increase is small compared to the other benefits**

77. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. *JAMA*. 1998 Aug 19;280(7):605-13

78. Levesque H, Courtois H. Estrogen therapy and venous thromboembolic disease. *Rev Med Interne*. 1997;18 Suppl 6:620s-625s

**3b) Studies where treatments with progestogens that have a NON-BIO-IDENTICAL STRUCTURE may increase the possibility of breast cancer development**

Some progestins (pregnanes) derived from progesterone stimulate apoptosis leading to breast cancer cell death; most cannot stimulate breast cancer cell multiplication; others such as estranes or gonanes derived from testosterone, stimulate breast cell multiplication in vitro through an estrogen receptor-mediated pathway

79. Sitruk-Ware R, Plu-Bureau G. Progestins and cancer. *Gynecol Endocrinol*. 1999 Jun;13 Suppl 4:3-9  
Department of Endocrinology, Hôpital Saint-Antoine, Paris.
80. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. *Int J Cancer*. 2005 Apr 10;114(3):448-54

**II. Arguments for the use of bio-identical estrogens and bio-identical progesterone in women**

**1) Studies that show that transdermal and bio-identical estradiol may be superior to oral and/or non-bio-identical estrogens.** Transdermal estradiol may avoid the adverse effects generally attributed to oral and/or non-bio-identical estrogens.

**1a) Transdermal or implant estradiol treatments provide normal estrone-estradiol levels, while oral estrogen treatments do not**

81. Slater CC, Hodis HN, Mack WJ, Shoupe D, Paulson RJ, Stanczyk FZ. Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women. *Menopause*. 2001 May-Jun;8(3):200-3
82. Lippert TH, Seeger H, Mueck AO. Estradiol metabolism during oral and transdermal estradiol replacement therapy in postmenopausal women. *Horm Metab Res*. 1998 Sep;30(9):598-600
83. Notelovitz M, Johnston M, Smith S, Kitchens C. Metabolic and hormonal effects of 25-mg and 50-mg 17 beta-estradiol implants in surgically menopausal women. *Obstet Gynecol*. 1987 Nov;70(5):749-54
84. Balfour JA, Heel RC. Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. *Drugs*. 1990 Oct;40(4):561-82

**1b) Transdermal estradiol treatments have no adverse effects on hemostatic factors and other cardiovascular risk factors (no CRP increase e.g.), while oral estrogen treatments do**

85. Meilahn EN. Hemostatic Factors and Ischemic Heart Disease Risk Among Postmenopausal Women. *J Thromb Thrombolysis*. 1995;1(2):125-131
86. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Jarvinen H. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. *Thromb Haemost*. 2001 Apr;85(4):619-25
87. Tikkanen MJ. The menopause and hormone replacement therapy: lipids, lipoproteins, coagulation and fibrinolytic factors. *Maturitas*. 1996 Mar;23(2):209-16
88. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. *Arterioscler Thromb Vasc Biol*. 1997 Nov;17(11):3071-8
89. Akkad AA, Halligan AW, Abrams K, al-Azzawi F. Differing responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal estrogen replacement therapy. *Obstet Gynecol*. 1997 Jan;89(1):97-103.
90. Nieto JJ, Cogswell D, Jesinger D, Hardiman P. Lipid effects of hormone replacement therapy with sequential transdermal 17-beta-estradiol and oral dydrogesterone. *Obstet Gynecol*. 2000 Jan;95(1):111-4
91. Perera M, Sattar N, Petrie JR, Hillier C, Small M, Connell JM, Lowe GD, Lumsden MA. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study. *J Clin Endocrinol Metab*. 2001 Mar;86(3):1140-3
92. Mueck AO, Seeger H, Lippert TH. Effect of transdermal versus oral estradiol administration on the excretion of vasoactive markers in postmenopausal women. *Gynakol Geburtshilfliche Rundsch*. 2000;40(2):61-7

93. Chen FP, Lee N, Soong YK, Huang KE. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors. *Menopause*. 2001 Sep-Oct;8(5):347-52

**1c) Transdermal estradiol treatments have a higher beneficial effect on weight, and lean and fat mass than oral estrogen treatments**

94. O'Sullivan AJ, Crampton LJ, Freund J, Ho KK. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. *J Clin Invest*. 1998 Sep 1;102(5):1035-40

Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney NSW 2010, Australia

95. Chmouliovsky L, Habicht F, James RW, Lehmann T, Campana A, Golay A. Beneficial effect of hormone replacement therapy on weight loss in obese menopausal women. *Maturitas*. 1999 Aug 16;32(3):147-53

**1d) Transdermal estradiol treatments spare the liver** (no liver accumulation of estrogens), while oral estrogens do not (first passage through the liver after absorption, resulting in an excessive accumulation of estrogens in the liver).

**1e) Transdermal estradiol treatments do not excessively increase the levels and liver production of plasma binding proteins such as SHBG, TBG, transcortine, GHBP, etc, while oral estrogens do.**

96. Steingold KA, Matt DW, DeZiegler D, Sealey JE, Fratkin M, Reznikov S. Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure. *J Clin Endocrinol Metab*. 1991 Aug;73(2):275-80

97. Van Erpecum KJ, Van Berge Henegouwen GP, Verschoor L, Stoelwinder B, Willekens FL. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. *Gastroenterology*. 1991 Feb;100(2):482-8

98. De Lignieres B, Basdevant A, Thomas G, Thalabard JC, Mercier-Bodard C, Conard J, Guyene TT, Mairon N, Corvol P, Guy-Grand B, et al. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. *J Clin Endocrinol Metab*. 1986 Mar;62(3):536-41

**1f) Other beneficial influences of transdermal estradiol compared to oral estrogens**

99. Lufkin EG, Ory SJ. Relative value of transdermal and oral estrogen therapy in various clinical situations. *Mayo Clin Proc*. 1994 Feb;69(2):131-5

**1g) Study where treatments with parenteral (especially transdermal) BIO-IDENTICAL estradiol proved to be safer than oral estradiol**

**Study where treatments with intravenous estradiol stimulate less tumour development than oral estradiol in animals**

100. Kerdelhue B, Jollette J. The influence of the route of administration of 17beta-estradiol, intravenous (pulsed) versus oral, upon DMBA-induced mammary tumour development in ovariectomised rats. *Breast Cancer Res Treat*. 2002 May;73(1):13-22

**1h) Studies where bio-identical and parenteral, in particular transdermal, estrogen treatments were associated with beneficial cardiovascular effects: more efficient and safer**

**Studies where low bio-identical estradiol levels are found in premenopausal women with coronary heart disease**

101. Hanke H, Hanke S, Ickrath O, Lange K, Bruck B, Muck AO, Seeger H, Zwirner M, Voisard R, Haasis R, Hombach V. Estradiol concentrations in premenopausal women with coronary heart disease. *Coron Artery Dis*. 1997 Aug-Sep;8(8-9):511-5

102. Bairey Merz CN, Johnson BD, Sharaf BL, Bittner V, Berga SL, Braunstein GD, Hodgson TK, Matthews KA, Pepine CJ, Reis SE, Reichek N, Rogers WJ, Pohost GM, Kelsey SF, Sopko G; WISE Study Group. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. *J Am Coll Cardiol*. 2003 Feb 5;41(3):413-9

**2) Studies with beneficial cardiovascular effects of estrogen therapy, generally obtained with the use of transdermal and bio-identical estradiol**

**Treatments with transdermal estradiol cause vasodilatation of the brachial and forearm arteries in postmenopausal women**

103. Blumel JE, Castelo-Branco C, Leal T, Gallardo L, Saini J, Ferron S, Haya J. Effects of transdermal estrogens on endothelial function in postmenopausal women with coronary disease. *Climacteric*. 2003 Mar;6(1):38-44
104. Gerhard M, Walsh BW, Tawakol A, Haley EA, Creager SJ, Seely EW, Ganz P, Creager MA. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. *Circulation*. 1998 Sep 22;98(12):1158-63
105. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO 3rd. Acute vascular effects of estrogen in postmenopausal women. *Circulation*. 1994 Aug;90(2):786-91

#### **Treatments with oral estradiol causes vasodilatation of the brachial artery in postmenopausal women**

106. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, Creager MA. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. *Ann Intern Med*. 1994 Dec 15;121(12):936-41.

#### **Treatments with intracoronary or intravenous estradiol cause vasodilatation and increased distensibility of coronary arteries**

107. Gilligan DM, Quyyumi AA, Cannon RO 3rd. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. *Circulation*. 1994 Jun;89(6):2545-51
108. Guetta V, Quyyumi AA, Prasad A, Panza JA, Waclawiw M, Cannon RO 3rd. The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. *Circulation*. 1997 Nov 4;96(9):2795-801
109. Gorodeski GI, Yang T, Levy MN, Goldfarb J, Utian WH. Modulation of coronary vascular resistance in female rabbits by estrogen and progesterone. *J Soc Gynecol Investig*. 1998 Jul-Aug;5(4):197-202

#### **Treatments with subcutaneous implants of 17-beta estradiol reduce coronary artery disease in female monkeys**

110. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. *Arteriosclerosis*. 1990 Nov-Dec;10(6):1051-7

#### **Treatments with subcutaneous injections of 17-beta-estradiol protect dogs against myocardial ischemia**

111. Kim YD, Chen B, Beauregard J, Kouretas P, Thomas G, Farhat MY, Myers AK, Lees DE. 17 beta-Estradiol prevents dysfunction of canine coronary endothelium and myocardium and reperfusion arrhythmias after brief ischemia/reperfusion. *Circulation*. 1996 Dec 1;94(11):2901-8

#### **Treatments with intravenous 17-beta-estradiol protect cats against acute myocardial ischemia**

112. Delyani JA, Murohara T, Nossuli TO, Lefer AM. Protection from myocardial reperfusion injury by acute administration of 17 beta-estradiol. *J Mol Cell Cardiol*. 1996 May;28(5):1001-8

#### **Treatments with transdermal estrogen reduce angina in postmenopausal women with angina and normal coronary arteries**

113. Roque M, Heras M, Roig E, Masotti M, Rigol M, Betriu A, Balasch J, Sanz G. Short-term effects of transdermal estrogen replacement therapy on coronary vascular reactivity in postmenopausal women with angina pectoris and normal results on coronary angiograms. *J Am Coll Cardiol*. 1998 Jan;31(1):139-43
114. Albertsson PA, Emanuelsson H, Milsom I. Beneficial effect of treatment with transdermal estradiol-17-beta on exercise-induced angina and ST segment depression in syndrome X. *Int J Cardiol*. 1996 Apr 19;54(1):13-20

#### **Treatments with implants of estradiol protect arteries of rats against atherosclerosis: prevent LDL-binding to arterial wall, reduce endothelial layer permeability**

115. Walsh BA, Mullick AE, Banka CE, Rutledge JC. 17beta-estradiol acts separately on the LDL particle and artery wall to reduce LDL accumulation. *J Lipid Res*. 2000 Jan;41(1):134-41

#### **Overview on vascular protective effects of estrogen**

116. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. *FASEB J*. 1996 Apr;10(5):615-24

#### **Treatments with oral estradiol cause vasodilatation and increased distensibility of arteries**

117. Angerer P, Kothny W, Stork S, von Schacky C. Hormone replacement therapy and distensibility of carotid arteries in postmenopausal women: a randomized, controlled trial. *J Am Coll Cardiol*. 2000 Nov 15;36(6):1789-96

**Treatments with transdermal estradiol reduce the carotid artery wall thickness and thus atherosclerosis in postmenopausal women**

118. Sumino H, Ichikawa S, Kasama S, Kumakura H, Takayama Y, Sakamaki T, Kurabayashi M. Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women. *Hypertens Res.* 2005 Jul;28(7):579-84
119. Takahashi K, Tanaka E, Murakami M, Mori-Abe A, Kawagoe J, Takata K, Ohmichi M, Kurachi H. Long-term hormone replacement therapy delays the age related progression of carotid intima-media thickness in healthy postmenopausal women. *Maturitas.* 2004 Oct 15;49(2):170-7
120. Hashimoto M, Miyao M, Akishita M, Hosoi T, Toba K, Kozaki K, Yoshizumi M, Ouchi Y. Effects of long-term and reduced-dose hormone replacement therapy on endothelial function and intima-media thickness in postmenopausal women. *Menopause.* 2002 Jan-Feb;9(1):58-64

**3) Studies where structurally BIO-IDENTICAL, especially TRANSDERMAL, estradiol treatment was shown to be breast cancer safer than treatments with non-bio-identical estrogens**

**EXOGENOUS BIO-IDENTICAL ESTRADIOL**

**In vitro study where a treatment with estradiol provided less epithelial proliferation than with conjugated estrogens in breast tissue, addition of bio-identical progesterone was even more reassuring as it greatly reduced the moderate bio-identical estradiol-induced proliferation**

121. Foidart JM, Colin C, Denoo X, Desreux J, Beliard A, Fournier S, de Lignieres B. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. *Fertil Steril.* 1998 May;69(5):963-9

**A study where the treatments associating transdermal estradiol to a progestogen other than MPA do not significantly increase the breast cancer risk (83% of participants took transdermal estradiol and other progestins than MPA were used)**

122. de Lignieres B, de Vathaire F, Fournier S, Urbinelli R, Allaert F, Le MG, Kuttenn F. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. *Climacteric.* 2002 Dec;5(4):332-40

**ENDOGENOUS BIO-IDENTICAL ESTRADIOL: Studies where high levels of endogenous estrogens are associated with less breast cancer or longer survival after breast cancer.**

**Studies where high levels of endogenous BIO-IDENTICAL estrogens are associated with a lower incidence of cancer or longer survival after breast cancer**

123. Holmberg L, Norden T, Lindgren A, Wide L, Degerman M, Adami HO. Pre-operative oestradiol levels - relation to survival in breast cancer. *Eur J Surg Oncol.* 2001 Mar;27(2):152-6
124. MacMahon B, Cole P, Brown JB, Aoki K, Lin TM, Morgan RW, Woo NC. Urine oestrogen profiles of Asian and North American women. *Int J Cancer.* 1974 Aug 15;14(2):161-7
125. MacMahon B, Cole P, Brown JB, Aoki K, Lin TM, Morgan RW, Woo N. Oestrogen profiles of Asian and North American women. *Lancet.* 1971 Oct 23;2(7730):900-2
126. Ursin G, Wilson M, Henderson BE, Kolonel LN, Monroe K, Lee HP, Seow A, Yu MC, Stanczyk FZ, Gentschein E. Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women? *Cancer Res.* 2001 Apr 15;61(8):3326-9
127. Ursin G, London S, Stanczyk FZ, Gentschein E, Paganini-Hill A, Ross RK, Pike MC. Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. *J Natl Cancer Inst.* 1999 Jun 16;91(12):1067-72
128. Lemon HM. Pathophysiologic considerations in the treatment of menopausal patients withoestrogens; the role of oestriol in the prevention of mammary carcinoma. *Acta Endocrinol Suppl. (Copenh).* 1980;233:17-27
129. Vorherr H, Messer RH. Breast cancer: potentially predisposing and protecting factors. Role of pregnancy, lactation, and endocrine status. *Am J Obstet Gynecol.* 1978 Feb 1;130(3):335-58

**A study where a high level of bio-identical estradiol at the moment of tumour surgery is associated with a better prognosis**

130. Holmberg L, Norden T, Lindgren A, Wide L, Degerman M, Adami HO. Pre-operative oestradiol levels - relation to survival in breast cancer. *Eur J Surg Oncol* 2001 Mar;27(2):152-6

**Studies where increased levels of bio-identical estrogens (such as those found in mature young women compared to the levels of girls before puberty) are associated with a lower cancer mortality**

131. Adami HO, Bergstrom R, Holmberg L, Klareskog L, Persson I, Ponten J. The effect of female sex hormones on cancer survival. A register-based study in patients younger than 20 years at diagnosis. *JAMA*. 1990 Apr 25;263(16):2189-93
132. Adami HO, Holmberg L, Persson I. Survival and age at diagnosis in breast cancer. *N Engl J Med*. 1987 ; 316(12): 750-2

**Studies where a high level of estriol compared to estrone and estradiol may be associated with a reduced incidence of breast cancer**

133. MacMahon B, Cole P, Brown JB, Aoki K, Lin TM, Morgan RW, Woo NC. Urine oestrogen profiles of Asian and North American women. *Int J Cancer*. 1974 Aug 15;14(2):161-7.
134. MacMahon B, Cole P, Brown JB, Aoki K, Lin TM, Morgan RW, Woo N. Oestrogen profiles of Asian and North American women. *Lancet*. 1971 Oct 23;2(7730):900-2.
135. Ursin G, Wilson M, Henderson BE, Kolonel LN, Monroe K, Lee HP, Seow A, Yu MC, Stanczyk FZ, Gentschein E. Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women? *Cancer Res*. 2001 Apr 15;61(8):3326-9.
136. Ursin G, London S, Stanczyk FZ, Gentschein E, Paganini-Hill A, Ross RK, Pike MC. Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. *J Natl Cancer Inst* 1999 Jun 16;91(12):1067-72
137. Lemon HM. Pathophysiologic considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma. *Acta Endocrinol Suppl (Copenh)* 1980;233:17-27
138. Vorherr H, Messer RH. Breast cancer: potentially predisposing and protecting factors. Role of pregnancy, lactation, and endocrine status. *Am J Obstet Gynecol* 1978 Feb 1;130(3):335-58

**Studies where breast cancer tumours rich in estrogen receptors (that thus responds well to estrogens) had a better prognosis (more differentiated, less malignant tumour)**

139. Salazar-Esquivel EL, Morales-Najar R, Calzada-Sanchez L. Infiltrating duct breast carcinoma: the role of estradiol and progesterone receptors. *Ginecol Obstet Mex*. 1994 Mar; 62: 85-90
140. Heise E, Gorlich M. Estradiol receptor and prognosis in human breast cancer and its metastases. *Neoplasma*. 1993;40(1):55-7
141. Nagai MA, Marques LA, Yamamoto L, Fujiyama CT, Brentani MM. Estrogen and progesterone receptor mRNA levels in primary breast cancer: association with patient survival and other clinical and tumor features. *Int J Cancer*. 1994 Nov 1; 59(3): 351-6
142. Mason BH, Holdaway IM, Mullins PR, Yee LH, Kay RG. Progesterone and estrogen receptors as prognostic variables in breast cancer. *Cancer Res* 1983 Jun;43(6):2985-90
143. Genazzani AR, Gadducci A, Gambacciani M. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Operadel Duomo, Pisa, Italy. *Climacteric* 2001 Sep;4(3):181-93

**TRANSDERMAL BIO-IDENTICAL ESTRADIOL:** Studies where treatments with estrogens taken by TRANSDERMAL ROUTE were associated with an increased risk of breast cancer or of conditions that may predispose to breast cancer

**A high urinary excretion of 16-alpha- OH-estrone is associated with increased risks of mammary hyperplasia and breast cancer**

144. Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW, Kuller LH. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. *Br J Cancer*. 1998 Nov;78(9):1250-5

**Treatments with oral estradiol cause a major increase in urinary 16-alpha- OH-estrone, not the case with transdermal estradiol**

145. Seeger H, Mueck AO, Lippert TH. Effect of norethisterone acetate on estrogen metabolism in postmenopausal women. *Horm Metab Res*. 2000 Oct;32(10):436-9

**Treatments with oral estrogens induce supraphysiological increases in estrone sulphate and estrone serum levels, not the case with transdermal estradiol**

146. Fahraeus L, Larsson-Cohn U. Oestrogens, gonadotrophins and SHBG during oral and cutaneous administration of oestradiol-17 beta to menopausal women. *Acta Endocrinol (Copenh)*. 1982 Dec;101(4):592-6

#### **4) Studies with beneficial or neutral effects of BIO-IDENTICAL PROGESTERONE on the cardiovascular system:**

##### **Treatment with vaginal progesterone gel delays exercise-induced myocardial ischemia in postmenopausal women with coronary heart disease and/or previous myocardial infarction**

147. Rosano GM, Webb CM, Chierchia S, Morgani GL, Gabraele M, Sarrel PM, de Ziegler D, Collins P. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogens on exercise-induced myocardial ischemia in postmenopausal women. *J Am Coll Cardiol.* 2000 Dec;36(7):2154-9

##### **Treatments with transdermal or intravenous progesterone (4 weeks) protect against severe prolonged coronary vasoconstriction, and reduce lipoprotein (a) in non and preatherosclerotic and atherosclerotic female monkeys**

148. Hermsmeyer RK, Mishra RG, Pavcnik D, Uchida B, Axthelm MK, Stanczyk FZ, Burry KA, Illingworth DR, Juan C, Nordt FJ. Prevention of coronary hyperreactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone. *Arterioscler Thromb Vasc Biol.* 2004 May;24(5):955-61

149. Minshall RD, Pavcnik D, Browne DL, Hermsmeyer K. Nongenomic vasodilator action of progesterone on primate coronary arteries. *J Appl Physiol.* 2002 Feb;92(2):701-8

##### **Treatments with intravenous progesterone increase coronary blood flow in pigs**

150. Molinari C, Battaglia A, Grossini E, Mary DA, Stoker JB, Surico N, Vacca G. The effect of progesterone on coronary blood flow in anaesthetized pigs. *Exp Physiol.* 2001 Jan;86(1):101-8

##### **Treatments with progesterone in vitro relax isolated animal coronary smooth muscles cells and arteries**

151. Jacob MK, White RE. Diazepam, gamma-aminobutyric acid, and progesterone open K(+) channels in myocytes from coronary arteries. *Eur J Pharmacol.* 2000 Sep 8;403(3):209-19.

152. Crews JK, Khalil RA. Antagonistic effects of 17 beta-estradiol, progesterone, and testosterone on Ca<sup>2+</sup> entry mechanisms of coronary vasoconstriction. *Arterioscler Thromb Vasc Biol.* 1999 Apr;19(4):1034-40

153. Jiang CW, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro. *Eur J Pharmacol.* 1992 Feb 11;211(2):163-7

##### **Treatments with progesterone have no negative effect on estradiol-induced protection of coronary arteries**

154. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. *Arteriosclerosis.* 1990 Nov-Dec;10(6):1051-7

155. Gerhard M, Walsh BW, Tawakol A, Haley EA, Creager SJ, Seely EW, Ganz P, Creager MA. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. *Circulation.* 1998 Sep 22;98(12):1158-63

#### **5) Studies with protective or neutral effects of bio-identical progesterone against breast cancer**

##### **5-1) EXOGENOUS BIO-IDENTICAL PROGESTERONE:**

##### **Studies where progesterone/progestogen treatment reduced the breast cancer risk in women with breast cysts**

156. Plu-Bureau G, Le MG, Sitruk-Ware R, Thalabard JC, Mauvais-Jarvis P. Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease. *Br J Cancer* 1994 Aug;70(2):270-7

157. Plu-Bureau G, Le MG, Thalabard JC, Sitruk-Ware R, Mauvais-Jarvis P. Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease. *Cancer Detect Prev* 1999;23(4):290-6 (*the physiological increase of endogenous progesterone during luteal phase coincided with a lower proliferation of breast epithelial cells*)

158. de Lignieres B. Effects of progestogens on the postmenopausal breast. *Climacteric.* 2002 Sep;5(3):229-35

**Treatments with transdermal estradiol alone or combined to a synthetically modified progestin increases the BC risk, but combined to bio-identical progesterone causes a -10% decrease of the breast cancer risk**

159. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. *Int J Cancer*. 2005 Apr 10;114(3):448-54

**5-2) ENDOGENOUS BIO-IDENTICAL PROGESTERONE:**

**Studies where lower endogenous BIO-IDENTICAL progesterone levels are associated with a lower overall or breast cancer incidence**

160. Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. *Am J Epidemiol* 1981 Aug;114(2):209-17

161. Adami HO, Bergstrom R, Holmberg L, Klareskog L, Persson I, Ponten J. The effect of female sex hormones on cancer survival. A register-based study in patients younger than 20 years at diagnosis. *JAMA*. 1990 Apr 25;263(16):2189-93

162. Adami HO, Holmberg L, Persson I. Survival and age at diagnosis in breast cancer. *N Engl J Med*. 1987 ; 316(12): 750-2

163. Mohr PE, Wang DY, Gregory WM, Richards MA, Fentiman IS. Serum progesterone and prognosis in operable breast cancer. *Br J Cancer*. 1996 Jun;73(12):1552-5

164. Badwe RA, Wang DY, Gregory WM, Fentiman IS, Chaudary MA, Smith P, Richards MA, Rubens RD. Serum progesterone at the time of surgery and survival in women with premenopausal operable breast cancer. *Eur J Cancer*. 1994;30A(4):445-8

**Studies where the prognosis is better when the breast cancer tumour is surgically removed in the luteal phase (particularly rich in progesterone)**

165. Cooper LS, Gillett CE, Patel NK, Barnes DM, Fentiman IS. Survival of premenopausal breast carcinoma patients in relation to menstrual cycle timing of surgery and estrogen receptor/progesterone receptor status of the primary tumor. *Cancer* 1999 Nov 15;86(10):2053-8

166. Senie RT, Rosen PP, Rhodes P, Lesser ML. Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival. *Ann Intern Med* 1991 Sep 1;115(5):337-42

167. Saad Z, Vincent M, Bramwell V, Stitt L, Duff J, Girotti M, Jory T, Heathcote G, Turnbull I, Garcia B. Timing of surgery influences survival in receptor-negative as well as receptor-positive breast cancer. *Eur J Cancer* 1994;30A(9):1348-52.

168. Saad Z, Bramwell V, Duff J, Girotti M, Jory T, Heathcote G, Turnbull I, Garcia B, Stitt L. Timing of surgery in relation to the menstrual cycle in premenopausal women with operable breast cancer. *Br J Surg* 1994 Feb;81(2):217-20

169. Veronesi U, Luini A, Mariani L, Del Vecchio M, Alvez D, Andreoli C, Giacobone A, Merson M, Pacetti G, Raselli R, et al. Effect of menstrual phase on surgical treatment of breast cancer. *Lancet* 1994 Jun 18;343(8912):1545-7

170. Holli K, Isola J, Hakama M. Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient—fact or fallacy. *Br J Cancer* 1995 Jan;71(1):124-7

171. Love RR, Duc NB, Dinh NV, Shen TZ, Havighurst TC, Allred DC, DeMets DL. Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer. *J Natl Cancer Inst* 2002 May 1;94(9):662-9

172. Goldhirsch A, Gelber RD, Castiglione M, O'Neill A, Thurlimann B, Rudenstam CM, Lindtner J, Collins J, Forbes J, Crivellari D, Coates A, Cavalli F, Simoncini E, Fey MF, Pagani O, Price K, Senn HJ. Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. *Ann Oncol* 1997 Aug;8(8):751-6

173. Vanek VW, Kadivar TF, Bourguet CC. Correlation of menstrual cycle at time of breast cancer surgery to disease-free and overall survival. *South Med J* 1997 Aug;90(8):780-8

174. Lemon HM, Rodriguez-Sierra JF. Timing of breast cancer surgery during the luteal menstrual phase may improve prognosis. *Nebr Med J* 1996 Mar;81(3):73-8

175. Badwe RA, Mitra I, Havaladar R. Timing of surgery during the menstrual cycle and prognosis of breast cancer. *J Biosci* 2000 Mar;25(1):113-2

176. Mangia A, De Lena M, Barletta A, Marzullo F, Attolico M, Stea B, Petroni S, Labriola A, Cellamare G, Digiesi G, Altieri R, Schittulli F, Paradiso A. Timing of breast cancer surgery within the menstrual cycle: tumor proliferative activity, receptor status and short-term clinical outcome. *J Exp Clin Cancer Res* 1998 Sep;17(3):317-23

177. Tsuchiya A, Furukawa H, Kanno M, Kimijima I, Abe R. Lack of the relationship between menstrual status and timing of surgery in survival of premenopausal patients with breast cancer. *Fukushima J Med Sci*. 1996 Dec;42(1-2):11-6.

178. Jager W, Sauerbrei W. Effect of timing of surgery during the menstrual cycle of premenopausal breast cancer patients. *Breast Cancer Res Treat* 1995 Jun;34(3):279-87

179. Zhang B, Shao Y, Wang C. Prognosis of patients with breast cancer related to the timing of operation during menstrual cycle: a report of 218 patients. *Zhonghua Zhong Liu Za Zhi* 1996 May;18(3):203-7
180. Milella M, Nistico C, Ferraresi V, Vaccaro A, Fabi A, D'Ottavio AM, Botti C, Giannarelli D, Lopez M, Cortesi E, Foggi CM, Antimi M, Terzoli E, Cognetti F, Papaldo P. Breast cancer and timing of surgery during menstrual cycle: a 5-year analysis of 248 premenopausal women. *Breast Cancer Res Treat* 1999 Jun;55(3):259-6

**Studies where the presence of mastalgia, breast cysts or uterin fibroids, conditions generally related to lower progesterone levels, is associated with an increased risk of breast cancer**

181. Plu-Bureau G, Thalabard JC, Sitruk-Ware R, Asselain B, Mauvais-Jarvis P. Cyclical mastalgia as a marker of breast cancer susceptibility: results of a case-control study among French women. *Br J Cancer* 1992 Jun;65(6):945-9
182. Deschamps M, Band PR, Coldman AJ, Hislop TG, Longley DJ. Clinical determinants of mammographic dysplasia patterns. *Cancer Detect Prev* 1996;20(6):610-9
183. Dixon JM, McDonald C, Elton RA, Miller WR. Risk of breast cancer in women with palpable breast cysts: a prospective study. Edinburgh Breast Group. *Lancet* 1999 May 22;353(9166):1742-5
184. Bruzzi P, Dogliotti L, Naldoni C, Bucchi L, Costantini M, Cicognani A, Torta M, Buzzi GF, Angeli A. Cohort study of association of risk of breast cancer with cyst type in women with gross cystic disease of the breast. *BMJ* 1997 Mar 29;314(7085):925-8
185. Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD Jr, Rados MS, Schuyler PA. Long-term risk of breast cancer in women with fibroadenoma. *N Engl J Med* 1994 Jul 7;331(1):10-5

**III. Arguments for the use of female hormones in women (as well bio-identical as non-bio-identical): the therapy may be neutral or even protect against breast cancer**

**I) Studies with cancer-preventive effects of estrogen (with or without progestogen) treatment**

**Studies where estrogen treatment was associated with a reduction of overall cancer occurrence**

186. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. *Arch Intern Med.* 1991; 151:75
187. Paganini Hill A. The Leisure World Cohort Study in The Treatment of the Postmenopausal Women- Lobo RA, Ed Paven Press – NY, 1994; p. 401: table 1.

**Studies where estrogen therapy reduced the incidence of breast cancer**

188. Gambrell RD Jr. Hormones in the etiology and prevention of breast and endometrial cancer. *South Med J.* 1984 Dec; 77(12): 1509-15.
189. Gambrell RD Jr, Maier RC, Sanders BI. Decreased incidence of breast cancer in postmenopausal estrogen progestogen users.. *Obstet Gynecol* 1983 Oct;62(4):435-43
190. Wingo PA, Layde PM, Lee NC, Rubin G, Ory HW.. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. *JAMA.* 1987 Jan 9; 257(2): 209-15.
191. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. *Obstet Gynecol.* 1979; 54: 74-9
192. Lauritzen C et al. Risks of endometrial and mammary cancer morbidity and mortality in long-term estrogen treatment. In *The Climacteric.-An Update*, ed by van Herendael H & B, Riphagen FE, Goessens L, van der Pars H Lancaster, England, MTP Press Ltd 1984; 207
193. Davelaar EM, Gerretsen G, Relyveld J.. No increase in the incidence of breast carcinoma with subcutaneous administration of estradiol *Ned Tijdsch Geneesk.* 1991 Apr 6 ; 135(14): 613-5
194. Rosenberg L, Miller DR, Kaufman DW, Helmrich SP, Stolley PD, Schottenfeld. D; Shapiro S. *Am J Epidemiol* 1984 Feb;119(2):167-76 Breast cancer and oral contraceptive use.
195. Kaufman DW, Miller DR, Rosenberg, Miller DR, Rosenberg L, Helmrich SP, Stolley P, Schottenfeld D, Shapiro S. Noncontraceptive estrogen use and the risk of breast *JAMA* 1984 Jul 6;252(1):63-7
196. Hammond CB, Jelovsek FR, Lee KI, WT, Parker. Effects of long term estrogen replacement therapy. II - Neoplasia. *Am J Obstet Gynecol.* 1979; 133: 537.
197. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to riskn of breast cancer in middle-aged women. *JAMA.* 1995 Jul 12;274(2):137-42 (*reduced BC risk for long time estrogen users ≥ 8 years*)

**Studies where the use of estrogens before having breast cancer was associated with smaller, less aggressive tumours with more positive hormone receptors (more differentiated, less malignant tumour), less metastases, better prognosis, less recurrence**

198. Gajdos C, Tartter PI, Babinszki A. Breast cancer diagnosed during hormone replacement therapy. *Obstet Gynecol* 2000 Apr;95(4):513-8
199. Holli K, Isola J, Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. *J Clin Oncol* 1998 Sep;16(9):3115-20
200. Ursin G, Tseng CC, Paganini-Hill A, Enger S, Wan PC, Formenti S, Pike MC, Ross RK. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? *Arch 1: J Clin Oncol* 2002 Feb 1;20(3):699-706
201. Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I. Prognostic characteristics in breast cancers after hormone replacement therapy. *Breast Cancer Res Treat.* 1996;38(3):325-34 (*"breast cancers occurring after treatment with HRT, especially the combined estrogen-progestin regimen, seem to have more favourable tumour features than tumours in non-treated women"*)

**Studies where the current use of estrogens at the moment of diagnosis of breast cancer was associated with a reduced breast cancer mortality**

202. Schairer C, Gail M, Byrne C, Rosenberg PS, Sturgeon SR, Brinton LA, Hoover RN. Estrogen replacement therapy and breast cancer survival in a large screening study. *J Natl Cancer Inst.* 1999 Feb 3;91(3):264-70
203. Nanda K, Bastian LA, Schulz K. Hormone replacement therapy and the risk of death from breast cancer: a systematic review. *Am J Obstet Gynecol.* 2002 Feb; 186 (2):325-34
204. Willis DB, Calle EE, Miracle-McMahill HL, Heath CW Jr. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. *Cancer Causes Control.* 1996 Jul;7(4):449-57

**Studies where the current use of estrogens at the moment of diagnosis of breast cancer was associated with a reduced overall mortality**

205. Ettinger B, Friedman GD, Bush T, Quesenberry CP Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. *Obstet Gynecol.* 1996 Jan;87(1):6-12
206. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. *Arch Intern Med* 1991; 151:75.
207. Jernstrom H, Frenander J, Ferno M, Olsson H. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. *Br J Cancer* 1999 Jul;80(9):1453-8
208. Hunt K, Vessey M, McPherson K. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. *Br J Obstet Gynaecol.* 1987; 94: 620-35 (*Lower overall mortality , but increased BC risk because of the use of unopposed ethinylestradiol*)

**Studies where estrogen therapy reduced overall mortality in women**

209. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE. Postmenopausal hormone therapy and mortality. *N Engl J Med* 1997; 336:1769-75

**Studies where estrogen therapy did not increase the breast cancer incidence, but increased the lifespan in women with familial risk of breast cancer**

210. Sellers TA, Mink PJ, Cerhan JR, Anderson KE, Kushi LH, Folsom AR. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. *Ann Intern Med.* 1997; 127:973-80 (*"HRT use in women with a family history of breast cancer is not associated with a significantly increased incidence of breast cancer but is associated with a significantly reduced total mortality rate, including overall cancer mortality"*)

**2) Studies with cancer protective effects of ESTROGEN TREATMENT (with or without progestogen) in women who have had breast cancer**

**Publication where the use of corrective female hormone therapy is advised two years after a surgical cure of a hormone negative tumour**

211. Birkhauser M. Hormone replacement therapy after treatment of breast carcinoma. *Schweiz Med Wochenschr.* 1998 Oct 24;128(43):1675-89

**Studies where the use of HRT reduced the recurrence of breast cancer in women with previous breast cancer**

212. Dew JE, Wren BG, Eden JA. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study. *Climacteric*. 2002;5(2):151-5
213. Dew J, Eden J, Beller E, Magarey C, Schwartz P, Crea P, Wren B. A cohort study of hormone replacement therapy given to women previously treated for breast cancer. *Climacteric*. 1998;1(2):137-42

**Studies where the use of HRT (pill, conjugated estrogens, estradiol patch, ..) did not increase the risk of breast cancer in women with previous breast cancer**

214. Peters GN, Fodera T, Sabol J, Jones S, Euhus D. Estrogen replacement therapy after breast cancer: a 12-year follow-up. *Ann Surg Oncol* 2001 Dec;8(10):828-32

**Studies where estrogen treatment of women with previous breast cancer reduced the breast cancer recurrence and increased longevity/survival time**

215. Peters GN, Fodera T, Sabol J, Jones S, Euhus D. Estrogen replacement therapy after breast cancer: a 12-year follow-up." *Ann Surg Oncol* 2001 Dec;8(10):828-32
216. Dew J, Eden J, Beller E, Magarey C, Schwartz P, Crea P, Wren B. A cohort study of hormone replacement therapy given to women previously treated for breast cancer. *Climacteric* 1998 Jun;1(2):137-42
217. Beckmann MW, Jap D, Djahansouzi S, Nestle-Kramling C, Kuschel B, Dall P, Brumm C, Bender HG. Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates. *Oncology* 2001;60(3):199-206
218. Natrajan PK, Soumakis K, Gambrell RD Jr. Estrogen replacement therapy in women with previous breast cancer. *Am J Obstet Gynecol* 1999 Aug;181(2):288-95
219. Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. *Am J Surg*. 1993 Mar;165(3):372-5
220. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. *J Natl Cancer Inst*. 2001;93(10):754-62
221. Durna EM, Wren BG, Heller GZ, Leader LR, Sjoblom P, Eden JA. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. *Med J Aust*. 2002 Oct 7;177(7):347-51
222. Meurer LN, Lena S. Cancer recurrence and mortality in women using hormone replacement therapy: meta-analysis. *J Fam Pract*. 2002 Dec;51(12):1056-62 (meta-analysis)

**Reviews that discuss the need of breast cancer patients to have HRT**

223. Seifert M, Galid A, Kubista E. Estrogen replacement therapy in women with a history of breast cancer. *Maturitas* 1999 Jun 21;32(2):63-8
224. Plu-Bureau G. Hormone replacement therapy after breast cancer. *J Gynecol Obstet Biol Reprod (Paris)* 2000 May;29(3):292-4 (review)
225. Marsden J, Whitehead M, A'Hern R, Baum M, Sacks N. Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? *Fertil Steril* 2000 Feb;73(2):292-9

**3) Administering female hormones to women who have had breast cancer may reduce breast cancer recurrence and mortality**

**Studies with cancer protective effects of ESTROGEN TREATMENT (with or without progestogen) in women who have had breast cancer**

**Publication where the use of corrective female hormone therapy is advised two years after a surgical cure of a hormone negative tumour**

226. Birkhauser M. Hormone replacement therapy after treatment of breast carcinoma. *Schweiz Med Wochenschr*. 1998 Oct 24;128(43):1675-89

**Studies where the use of HRT reduced the recurrence of breast cancer in women with previous breast cancer**

227. Dew JE, Wren BG, Eden JA. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study. *Climacteric*. 2002;5(2):151-5
228. Dew J, Eden J, Beller E, Magarey C, Schwartz P, Crea P, Wren B. A cohort study of hormone replacement therapy given to women previously treated for breast cancer. *Climacteric*. 1998;1(2):137-42

**Studies where the use of HRT (pill, conjugated estrogens, estradiol patch, ..) did not increase the risk of breast cancer in women with previous breast cancer**

229. Peters GN, Fodera T, Sabol J, Jones S, Euhus D. Estrogen replacement therapy after breast cancer: a 12-year follow-up. *Ann Surg Oncol* 2001 Dec;8(10):828-32

**Studies where estrogen treatment of women with previous breast cancer reduced the breast cancer recurrence and increased longevity/survival time**

230. Peters GN, Fodera T, Sabol J, Jones S, Euhus D. Estrogen replacement therapy after breast cancer: a 12-year follow-up." *Ann Surg Oncol* 2001 Dec;8(10):828-32

231. Dew J, Eden J, Beller E, Magarey C, Schwartz P, Crea P, Wren B. A cohort study of hormone replacement therapy given to women previously treated for breast cancer. *Climacteric* 1998 Jun;1(2):137-42

232. Beckmann MW, Jap D, Djahansouzi S, Nestle-Kramling C, Kuschel B, Dall P, Brumm C, Bender HG. Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates. *Oncology* 2001;60(3):199-206

233. Natrajan PK, Soumakis K, Gambrell RD Jr. Estrogen replacement therapy in women with previous breast cancer. *Am J Obstet Gynecol* 1999 Aug;181(2):288-95

234. Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. *Am J Surg*. 1993 Mar;165(3):372-5

235. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. *J Natl Cancer Inst*. 2001;93(10):754-62

236. Durna EM, Wren BG, Heller GZ, Leader LR, Sjoblom P, Eden JA. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. *Med J Aust*. 2002 Oct 7;177(7):347-51

237. Meurer LN, Lena S. Cancer recurrence and mortality in women using hormone replacement therapy: meta-analysis. *J Fam Pract*. 2002 Dec;51(12):1056-62 (meta-analys)

**Reviews that discuss the need of breast cancer patients to have HRT**

238. Seifert M, Galid A, Kubista E. Estrogen replacement therapy in women with a history of breast cancer. *Maturitas* 1999 Jun 21;32(2):63-8

239. Plu-Bureau G. Hormone replacement therapy after breast cancer. *J Gynecol Obstet Biol Reprod (Paris)* 2000 May;29(3):292-4 (review)

240. Marsden J, Whitehead M, A'Hern R, Baum M, Sacks N. Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? *Fertil Steril* 2000 Feb;73(2):292-9

**Studies where treatments with progestogens reduced the breast cancer risk**

241. Lauritzen C et al. Risks of endometrial and mammary cancer morbidity and mortality in long-term estrogen treatment. In *The Climacteric -An Update*, ed by van Herendael H & B, Riphagen FE, Goessens L, van der Pars H Lancaster, England, MTP Press Ltd 1984; 207

242. Gambrell RD Jr, Maier RC, Sanders BI. Decreased incidence of breast cancer in postmenopausal estrogen progestogen users. *Obstet Gynecol* 1983 Oct;62(4):435-43

243. Gambrell RD Jr. Hormones in the etiology and prevention of breast and endometrial cancer. *South Med J*. 1984 Dec; 77(12): 1509-15

**4) NO EFFECT OF HRT ON BREAST CANCER RISK**

**Studies with no increased breast cancer risk (or a nonsignificant lower risk) with the use of female hormone replacement therapy (conjugated estrogens or other estrogens):**

244. Kaufman DW, Miller DR, Rosenberg L, Miller DR, Rosenberg L, Helmrich SP, Stolley P, Schottenfeld D, Shapiro S. Noncontraceptive estrogen use and the risk of breast cancer. *JAMA* 1984 Jul 6;252(1):63-7

245. Hammond CB, Jelovsek FR, Lee KI, WT, Parker. Effects of long term estrogen replacement therapy. II - Neoplasia. *Am J Obstet Gynecol*. 1979; 133: 537-47

246. Rosenberg L, Miller DR, Kaufman DW, Helmrich SP, Stolley PD, Schottenfeld. D; Shapiro S. Breast cancer and oral contraceptive use. *Am J Epidemiol* 1984 Feb;119(2):167-76

247. Wingo PA, Layde PM, Lee NC, Rubin G, Ory HW. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. *JAMA*. 1987 Jan 9; 257(2): 209-15

248. Peters GN, Fodera T, Sabol J, Jones S, Euhus D. Estrogen replacement therapy after breast cancer: a 12-year follow-up. *Ann Surg Oncol* 2001 Dec;8(10):828-32

249. Basavilvazo Rodriguez MA, Diaz Quiroz A, Lemus Rocha R, Angeles Victoria L, Zarate A, Hernandez-Valencia M. Hormonal replacement therapy and breast cancer. A case-control study. *Ginecol Obstet Mex*. 2004 Jan;72(1):10-5

**5) Concomitant use of testosterone (which has progestative activity, but can convert into estradiol) may reduce the breast cancer risk when using female hormone therapy in women**

250. Dimitrakakis C, Jones RA, Liu A, Bondy CA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. *Menopause*. 2004 Sep-Oct;11(5):531-535
251. Natrajan PK, Soumakis K, Gambrell RD Jr. Estrogen replacement therapy in women with previous breast cancer. *Am J Obstet Gynecol* 1999 Aug;181(2):288-95

#### **IV. Arguments for the use of female hormones in women with female hormone deficiency: the therapy may preserve and improve body, mind and longevity:**

The importance of estrogen & progesterone for women in pre- and postmenopause is supported by evidence that the lack of these hormones is associated with psychic and physical diseases, and that their use in corrective hormone therapy reduces the severity of the associated psychic and physical diseases

##### **Estrogens and psychic well-being**

###### **Lower estrogen levels are associated with a lower quality of life and a greater fatigue**

Studer DW. Clinical symptoms of estrogen deficiency in Estrogen Deficiency: causes & consequence, 1996, Ed. RW Staw, The Parthenon Publishing Group, New-York, USA

36. Freedman MA. Quality of life and menopause: the role of estrogen. *J Womens Health (Larchmt)*. 2002 Oct;11(8):703-18
37. Carette S, Dessureault M, Belanger A. Fibromyalgia and sex hormones. *J Rheumatol*. 1992 May;19(5):831

###### **Lower quality of life and fatigue improve with estrogen treatment**

38. Czarnecka D, Klocek M, Betkowska-Korpala B, Jankowski P, Olszanecka A, Kawecka-Jaszcz K. Influence of hormone replacement therapy on the quality of life in postmenopausal women with hypertension. *Przegl Lek*. 2000;57(7-8):397-401
39. Burger HG, Hailes J, Menelaus M, Nelson J, Hudson B, Balazs N. The management of persistent menopausal symptoms with oestradiol-testosterone implants: clinical, lipid and hormonal results. *Maturitas*. 1984 Dec;6(4):351-8
40. Dobs AS, Nguyen T, Pace C, Roberts CP. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. *J Clin Endocrinol Metab*. 2002 Apr;87(4):1509-16
41. Nathorst-Boos J, Wiklund I, Mattsson LA, Sandin K, von Schoultz B. Is sexual life influenced by transdermal estrogen therapy? A double blind placebo controlled study in postmenopausal women. *Acta Obstet Gynecol Scand*. 1993 Nov;72(8):656-60
42. Wendlova J. Effect of Kliogest on bone metabolism, bone mineral density and quality of life in postmenopausal patients. *Vnitr Lek*. 1998 Aug;44(8):464-8
43. Gorins A, Espie M, Bedairia N, Perret F, Tournant B, Novak H, Lucchi-Angelier E, Marty M. Hormone replacement therapy in breast cancer patients: a study of 230 patients, with a case-control study. *Gynecol Obstet Fertil*. 2003 Jul-Aug;31(7-8):614-9
44. Gambacciani M, Ciaponi M, Cappagli B, Monteleone P, Benussi C, Bevilacqua G, Genazzani AR. Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. *Maturitas*. 2003 Feb 25;44(2):157-63
45. Derman RJ, Dawood MY, Stone S. Quality of life during sequential hormone replacement therapy – a placebo-controlled study. *Int J Fertil Menopausal Stud*. 1995 Mar-Apr;40(2):73-8
46. Collins A, Hanson U, Eneroth P, Hagenfeldt K, Lundberg U, Frankenhaeuser M. Psychophysiological stress responses in postmenopausal women before and after hormonal replacement therapy. *Hum Neurobiol*. 1982;1(2):153-9
47. Ulrich LG, Barlow DH, Sturdee DW, Wells M, Campbell MJ, Nielsen B, Bragg AJ, Vessey MP. Quality of life and patient preference for sequential versus continuous combined HRT: the UK Kliofem multicenter study experience. UK Continuous Combined HRT Study Investigators. *Int J Gynaecol Obstet*. 1997 Oct;59 Suppl 1:S11-7
48. Gelfand MM, Moreau M, Ayotte NJ, Hilditch JR, Wong BA, Lau CY. Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: a placebo-controlled study. *Menopause*. 2003 Jan-Feb;10(1):29-36
49. Barrett-Connor E, Young R, Notelovitz M, Sullivan J, Wiita B, Yang HM, Nolan J. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. *J Reprod Med*. 1999 Dec;44(12):1012-20
50. Bech P, Munk-Jensen N, Obel EB, Ulrich LG, Eiken P, Nielsen SP. Combined versus sequential hormonal replacement therapy: a double-blind, placebo-controlled study on quality of life-related outcome measures. *Psychother Psychosom*. 1998 Jul-Oct;67(4-5):259-65
51. Wu MH, Pan HA, Wang ST, Hsu CC, Chang FM, Huang KE. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. *Climacteric*. 2001 Dec;4(4):314-9
52. Pornel B. Efficacy and safety of Menorest in two positive-controlled studies. *Eur J Obstet Gynecol Reprod Biol*. 1996 Apr;64 Suppl:S35-7

53. Karlberg J, Mattsson LA, Wiklund I. A quality of life perspective on who benefits from estradiol replacement therapy. *Acta Obstet Gynecol Scand*. 1995 May;74(5):367-72
54. Limouzin-Lamothe MA, Mairon N, Joyce CR, Le Gal M. Quality of life after the menopause: influence of hormonal replacement therapy. *Am J Obstet Gynecol*. 1994 Feb;170(2):618-24
55. Iversen OE, Eid AB, Johannesen KH, Nyland B, Lovset T. Transdermal estrogen treatment. A placebo controlled study. *Tidsskr Nor Laegeforen*. 1991 Aug 30;111(20):2544-6
56. Wiklund I, Karlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. *Am J Obstet Gynecol*. 1993 Mar;168(3 Pt 1):824-30
57. Wiklund I, Berg G, Hammar M, Karlberg J, Lindgren R, Sandin K. Long-term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women. *Maturitas*. 1992 Mar;14(3):225-36
58. Wiklund I, Holst J, Karlberg J, Mattsson LA, Samsioe G, Sandin K, Uvebrant M, von Schoultz B. A new methodological approach to the evaluation of quality of life in postmenopausal women. *Maturitas*. 1992 Mar;14(3):211-24
59. Hilditch JR, Lewis J, Ross AH, Peter A, van Maris B, Franssen E, Charles J, Norton P, Dunn EV. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women. *Maturitas*. 1996 Jul;24(3):177-84
60. Hall G, Pripp U, Schenck-Gustafsson K, Landgren BM. Long-term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. *Maturitas*. 1998 Jan 12;28(3):235-42
61. Rigano A, Rigano M, Cancellieri F, Pulle C. Sexually and well-being in early menopause. Effect of transdermal estradiol therapy. *Panminerva Med*. 2001 Jun;43(2):115-8.
62. Adamson DL, Webb CM, Collins P. Esterified estrogens combined with methyltestosterone improve emotional well-being in postmenopausal women with chest pain and normal coronary angiograms. *Menopause*. 2001 Jul-Aug;8(4):233-8
63. Collins A, Hanson U, Eneroth P, Hagenfeldt K, Lundberg U, Frankenhaeuser M. Psychophysiological stress responses in postmenopausal women before and after hormonal replacement therapy. *Hum Neurobiol*. 1982;1(2):153-9
64. Best NR, Rees MP, Barlow DH, Cowen PJ. Effect of estradiol implant on noradrenergic function and mood in menopausal subjects. *Psychoneuroendocrinology*. 1992;17(1):87-93
65. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. *Clin Obstet Gynaecol*. 1977 Apr;4(1):31-47

### **Vasomotor symptoms: Improvement with**

#### ***Estradiol treatment***

66. Ettinger B. Vasomotor symptom relief versus unwanted effects: role of estrogen dosage. *Am J Med*. 2005 Dec 19;118(12 Suppl 2):74-8vmettinger@aol.com
67. Tan D, Haines CJ, Limpaphayom KK, Holinka CF, Ausmanas MK. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) study. *Maturitas*. 2005 Sep 16;52(1):35-51
68. Nedstrand E, Wijma K, Wyon Y, Hammar M. Applied relaxation and oral estradiol treatment of vasomotor symptoms in postmenopausal women. *Maturitas*. 2005 Jun 16;51(2):154-62
69. Wyon Y, Wijma K, Nedstrand E, Hammar M. A comparison of acupuncture and oral estradiol treatment of vasomotor symptoms in postmenopausal women. *Climacteric*. 2004 Jun;7(2):153-64
70. Archer DF; EstroGel Study Group. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. *Menopause*. 2003 Nov-Dec;10(6):516-21
71. Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol. *Menopause*. 2000 Sep-Oct;7(5):310-7
72. Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17beta-estradiol dose for treating vasomotor symptoms. *Obstet Gynecol*. 2000 May;95(5):726-31
73. Simon J, Klaiber E, Wiita B, Bowen A, Yang HM. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. *Menopause*. 1999 Summer;6(2):138-46
74. Rozenberg S, Ylikorkala O, Arrenbrecht S. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids. *Int J Fertil Womens Med*. 1997;42 Suppl 2:376-87

#### ***Progesterone treatment***

75. Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. *Obstet Gynecol.* 1999 Aug;94(2):225-8

**Depression: the association with lower estrogen levels**

76. Almeida OP, Lautenschlager N, Vasikaram S, Leedman P, Flicker L. Association between physiological serum concentration of estrogen and the mental health of community-dwelling postmenopausal women age 70 years and over. *Am J Geriatr Psychiatry.* 2005 Feb;13(2):142-9

**Depression: the improvement with estrogen treatment**

77. Carranza-Lira S, Valentino-Figueroa ML. Estrogen therapy for depression in postmenopausal women. *Int J Gynaecol Obstet.* 1999 Apr;65(1):35-8
78. Dittkoff EC, Cray WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postmenopausal women. *Obstet Gynecol.* 1991 Dec;78(6):991-5
79. Lawrie TA, Herxheimer A, Dalton K. Oestrogens and progestogens for preventing and treating postnatal depression. *Cochrane Database Syst Rev.* 2000;(2):CD001690
80. Rudolph I, Palombo-Kinne E, Kirsch B, Mellinger U, Breitbarth H, Graser T. Influence of a continuous combined HRT (2 mg estradiol valerate and 2 mg dienogest) on postmenopausal depression. *Climacteric.* 2004 Sep;7(3):301-11
81. Rasgon NL, Altshuler LL, Fairbanks LA, Dunkin JJ, Davtyan C, Elman S, Rapkin AJ. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. *J Clin Psychiatry.* 2002;63 Suppl 7:45-8
82. de Lignieres B, Vincens M. Differential effects of exogenous oestradiol and progesterone on mood in post-menopausal women: individual dose/effect relationship. *Maturitas.* 1982 Apr;4(1):67-72
83. Best NR, Rees MP, Barlow DH, Cowen PJ. Effect of estradiol implant on noradrenergic function and mood in menopausal subjects. *Psychoneuroendocrinology.* 1992;17(1):87-93
84. [Brincat M, Magos A, Studd JW, Cardozo LD, O'Dowd T, Wardle PJ, Cooper D.](#) Subcutaneous hormone implants for the control of climacteric symptoms. A prospective study. *Lancet.* 1984 Jan 7;1(8367):16-8
85. Sherwin BB, Gelfand MM. Sex steroids and affect in the surgical menopause: a double-blind, cross-over study. *Psychoneuroendocrinology.* 1985;10(3):325-35
86. Gregoire AJ, Kumar R, Everitt B, Henderson AF, Studd JW. Transdermal oestrogen for treatment of severe postnatal depression. *Lancet.* 1996 Apr 6;347(9006):930-3
87. Ahokas A, Kaukoranta J, Wahlbeck K, Aito M. Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17beta-estradiol: a preliminary study. *J Clin Psychiatry.* 2001 May;62(5):332-6
88. Nathorst-Boos J, von Schoultz B, Carlstrom K. Elective ovarian removal and estrogen replacement therapy--effects on sexual life, psychological well-being and androgen status. *J Psychosom Obstet Gynaecol.* 1993 Dec;14(4):283-93
89. Soares CN, Almeida OP, Joffe H, Cohen LS. Arch Gen Psychiatry. 2001 Jun;58(6):529-34. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. *Arch Gen Psychiatry.* 2001 Jun;58(6):537-8.

**Anxiety: the association with lower progesterone levels**

90. Abraham GE. Nutritional factors in the etiology of the premenstrual tension syndromes. *J Reprod Med.* 1983 Jul;28(7):446-64

**Anxiety: the improvement with**

***Estrogen and progestogen treatment:***

91. Collins A, Hanson U, Eneroth P, Hagenfeldt K, Lundberg U, Frankenhaeuser M. Psychophysiological stress responses in postmenopausal women before and after hormonal replacement therapy. *Hum Neurobiol.* 1982;1(2):153-9

***Estrogen treatment***

92. Best NR, Rees MP, Barlow DH, Cowen PJ. Effect of estradiol implant on noradrenergic function and mood in menopausal subjects. *Psychoneuroendocrinology.* 1992;17(1):87-93
93. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. *Clin Obstet Gynaecol.* 1977 Apr;4(1):31-47

94. Montgomery JC, Appleby L, Brincat M, Versi E, Tapp A, Fenwick PB, Studd JW. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. *Lancet*. 1987 Feb 7;1(8528):297-9
95. Nathorst-Boos J, von Schoultz B, Carlstrom K. Elective ovarian removal and estrogen replacement therapy - effects on sexual life, psychological well-being and androgen status. *J Psychosom Obstet Gynaecol*. 1993 Dec;14(4):283-93

#### ***Progesterone treatment:***

96. Wieland S, Lan NC, Mirasedeghi S, Gee KW. Anxiolytic activity of the progesterone metabolite 5 alpha-pregnan-3 alpha-o1-20-one. *Brain Res*. 1991 Nov 29;565(2):263-8.
97. Picazo O, Fernandez-Guasti A. Anti-anxiety effects of progesterone and some of its reduced metabolites: an evaluation using the burying behavior test. *Brain Res*. 1995 May 22;680(1-2):135-41.
98. Bitran D, Shiekh M, McLeod M. Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABAA receptors. *J Neuroendocrinol*. 1995 Mar;7(3):171-7
99. Baker ER, Best RG, Manfredi RL, Demers LM, Wolf GC. Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms in patients with premenstrual syndrome. *J Assist Reprod Genet*. 1995 Mar;12(3):205-9
100. Bitran D, Purdy RH, Kellogg CK. Anxiolytic effect of progesterone is associated with increases in cortical allopregnanolone and GABAA receptor function. *Pharmacol Biochem Behav*. 1993 Jun;45(2):423-8

#### **Memory loss and Alzheimer's disease: the association with lower estrogen levels**

101. Hoff AL, Kremen WS, Wieneke MH, Lauriello J, Blankfeld HM, Faustman WO, Csernansky JG, Nordahl TE. Association of estrogen levels with neuropsychological performance in women with schizophrenia. *Am J Psychiatry*. 2001 Jul;158(7):1134-9
102. Kampen DL, Sherwin BB. Estradiol is related to visual memory in healthy young men. *Behav Neurosci*. 1996 Jun;110(3):613-7

#### **Memory loss and Alzheimer's disease: the improvement with**

##### ***Estrogen treatment***

103. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. *Lancet*. 1996 Aug 17;348(9025):429-32
104. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. *Arch Intern Med*. 1996 Oct 28;156(19):2213-7
105. Henderson VW, Watt L, Buckwalter JG. Cognitive skills associated with estrogen replacement in women with Alzheimer's disease. *Psychoneuroendocrinology*. 1996 May;21(4):421-30
106. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. *Dementia*. 1995 Mar-Apr;6(2):99-1
107. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. *Endocr J*. 1994 Aug;41(4):361-71

##### ***Estrogen and progesterone treatment***

108. Linzmayer L, Semlitsch HV, Saletu B, Bock G, Saletu-Zyhlarz G, Zoghiami A, Gruber D, Metka M, Huber J, Oettel M, Graser T, Grunberger J. Double-blind, placebo-controlled psychometric studies on the effects of a combined estrogen-progestin regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients. *Arzneimittelforschung*. 2001;51(3):238-45
109. Asthana S, Baker LD, Craft S, Stanczyk FZ, Veith RC, Raskind MA, Plymate SR. High-dose estradiol improves cognition for women with AD: results of a randomized study. *Neurology* 2001 Aug 28;57(4):605-12
110. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. *Psychoneuroendocrinology*. 1988;13(4):345-57
111. Smith YR, Giordani B, Lajiness-O'Neill R, Zubieta JK. Long-term estrogen replacement is associated with improved nonverbal memory and attentional measures in postmenopausal women. *Fertil Steril*. 2001 Dec;76(6):1101-7
112. Stein DG. Brain damage, sex hormones and recovery: a new role for progesterone and estrogen? *Trends Neurosci*. 2001 Jul;24(7):386-91
113. Sandstrom NJ, Williams CL. Memory retention is modulated by acute estradiol and progesterone replacement. *Behav Neurosci*. 2001 Apr;115(2):384-93

#### **Sleep disorder: the association with lower estrogen levels**

114. Hollander LE, Freeman EW, Sammel MD, Berlin JA, Grisso JA, Battistini M. Sleep quality, estradiol levels, and behavioral factors in late reproductive age women. *Obstet Gynecol.* 2001 Sep;98(3):391-7

#### **Sleep disorder: the improvement with estrogen treatment**

115. Keefe DL, Watson R, Naftolin F. Hormone replacement therapy may alleviate sleep apnea in menopausal women: a pilot study. *Menopause.* 1999 Fall;6(3):196-200.
116. Antonijevic IA, Stalla GK, Steiger A. Modulation of the sleep electroencephalogram by estrogen replacement in postmenopausal women. *Am J Obstet Gynecol.* 2000 Feb;182(2):277-82.
117. Schiff I, Regestein Q, Tulchinsky D, Ryan KJ. Effects of estrogens on sleep and psychological state of hypogonadal women. *JAMA.* 1979 Nov 30;242(22):2405-4
118. Sarti CD, Chiantera A, Graziottin A, Ognisanti F, Sidoli C, Mincigrucci M, Parazzini F; Gruppo di Studio IperAOGOI. Hormone therapy and sleep quality in women around menopause. *Menopause.* 2005 Sep-Oct;12(5):545-51

#### **Sleep disorder: the improvement with progesterone treatment**

119. Montplaisir J, Lorrain J, Denesle R, Petit D. Sleep in menopause: differential effects of two forms of hormone replacement therapy. *Menopause.* 2001 Jan-Feb;8(1):10-6

#### **Loss of sexual drive, sensitivity and potency: the association with lower estrogen levels**

120. Carani C, Rochira V, Faustini-Fustini M, Balestrieri A, Granata AR. Role of oestrogen in male sexual behavior: insights from the natural model of aromatase deficiency. *Clin Endocrinol (Oxf)* 1999 Oct;51(4):517-24
121. Cutler WB, Garcia CR, McCoy N. Perimenopausal sexuality. *Arch Sex Behav* 1987;16(3):225-34

#### **Loss of sexual drive, sensitivity and potency: The efficacy of female hormone treatments**

122. Castelo-Branco C, Vicente JJ, Figueras F, Sanjuan A, Martinez de Osaba MJ, Casals E, Pons F, Balasch J, Vanrell JA. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. *Maturitas.* 2000 Feb 15;34(2):161-8
123. Sherwin BB. Randomized clinical trials of combined estrogen-androgen preparations: effects on sexual functioning. *Fertil Steril.* 2002 Apr;77 Suppl 4:S49-54.
124. Matuszkiewicz-Rowinska J, Skorzevska K, Radowicki S, Sokalski A, Przedlacki J, Niemczyk S, Wlodarczyk D, Puka J, Switalski M. The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. *Nephrol Dial Transplant* 1999 May;14(5):1238-43

#### **Estrogens and physical appearance/body composition**

##### **Sarcopenia: association with low estradiol and estrone levels**

125. Iannuzzi-Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. *J Gerontol A Biol Sci Med Sci.* 2002 Dec;57(12):M772-7

##### **Sarcopenia: the improvement with estradiol treatment**

126. Sipila S, Taaffe DR, Cheng S, Puolakka J, Toivanen J, Suominen H. Effects of hormone replacement therapy and high-impact physical exercise on skeletal muscle in post-menopausal women: a randomized placebo-controlled study. *Clin Sci (Lond).* 2001 Aug;101(2):147-57

##### **Lean body mass: the improvement with estradiol ( as well transdermal as oral) treatment**

127. Hassager C, Christiansen C. Estrogen/gestagen therapy changes soft tissue body composition in postmenopausal women. *Metabolism.* 1989 Jul;38(7):662-5
128. Sorensen MB, Rosenfalck AM, Hojgaard L, Ottesen B. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. *Obes Res.* 2001 Oct;9(10):622-6
129. Davis SR, Walker KZ, Strauss BJ. Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. *Menopause.* 2000 Nov-Dec;7(6):395-401

### **Hirsutism: the improvement with estrogen treatment**

130. Benjamin F, Kolodny HD, Schwartz ED. The comparative effects of the administration of cortisone, estrogen-progestin, and placebo on the clinical manifestations of the polycystic ovary (Stein-Leventhal) syndrome. *J Reprod Med.* 1971 Jun;6(6):266-9
131. Wieland RG, Zorn E. Effect of chronic combined glucocorticoid and estrogen on serum androgens and androgen binding in hirsutism. *Cutis.* 1979 Apr;23(4):458-60
132. Kuttann F, Rigaud C, Wright F, Mauvais-Jarvis P. Treatment of hirsutism by oral cyproterone acetate and percutaneous estradiol. *J Clin Endocrinol Metab.* 1980 Nov;51(5):1107-11
133. Jasonni VM, Bulletti C, Naldi S, Di Cosmo E, Cappuccini F, Flamigni C. Treatment of hirsutism by an association of oral cyproterone acetate and transdermal 17 beta-estradiol. *Fertil Steril.* 1991 Apr;55(4):742-5
134. Azziz R, Ochoa TM, Bradley EL Jr, Potter HD, Boots LR. Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study. *J Clin Endocrinol Metab.* 1995 Dec;80(12):3406-11
135. Beigi A, Sobhi A, Zarrinkoub F. Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. *Int J Gynaecol Obstet.* 2004 Oct;87(1):29-33.
136. Venturoli S, Ravaioli B, Bagnoli A, Colombo FM, Macrelli S, Iadarola I, Vianello F, Mancini F, Flamigni C. Contraceptive and therapeutic effectiveness of two low-dose ethinylestradiol and cyproterone acetate regimens in the treatment of hirsute patients. *Eur J Contracept Reprod Health Care.* 1998 Mar;3(1):29-33

### **Estrogen and age-related diseases**

#### **Hypercholesterolemia: the association with lower estrogen levels**

137. Lamon-Fava S, Barnett JB, Woods MN, McCormack C, McNamara JR, Schaefer EJ, Longcope C, Rosner B, Gorbach SL. Differences in serum sex hormone and plasma lipid levels in caucasian and african-american premenopausal women *J Clin Endocrinol Metab.* 2005 Aug;90(8):4516-20

#### **Hypercholesterolemia: the improvement with**

##### ***Estrogen treatment***

138. Darko DA, Dornhorst A, Kennedy G, Mandeno RC, Seed M. Glycaemic control and plasma lipoproteins in menopausal women with Type 2 diabetes treated with oral and transdermal combined hormone replacement therapy. *Diabetes Res Clin Pract* 2001 Dec;54(3):157-64
139. Nanda S, Gupta N, Mehta HC, Sangwan K. Effect of oestrogen replacement therapy on serum lipid profile. *Aust N Z J Obstet Gynaecol.* 2003 Jun;43(3):213-6
140. Sanada M, Tsuda M, Kodama I, Sakashita T, Nakagawa H, Ohama K. Substitution of transdermal estradiol during oral estrogen-progestin therapy in postmenopausal women: effects on hypertriglyceridemia. *Menopause.* 2004 May-Jun;11(3):331-6
141. Dansuk R, Unal O, Karageyim Y, Esim E, Turan C. Evaluation of the effect of tibolone and transdermal estradiol on triglyceride level in hypertriglyceridemic and normotriglyceridemic postmenopausal women. *Gynecol Endocrinol.* 2004 May;18(5):233-9
142. Balci H, Altunyurt S, Acar B, Fadiloglu M, Kirkali G, Onvural B. Effects of transdermal estrogen replacement therapy on plasma levels of nitric oxide and plasma lipids in postmenopausal women. *Maturitas.* 2005 Apr 11;50(4):289-93
143. Hemelaar M, van der Mooren MJ, Mijatovic V, Bouman AA, Schijf CP, Kroeks MV, Franke HR, Kenemans P. Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study *Menopause.* 2003 Nov-Dec;10(6):550-8
144. Vigna GB, Donega P, Zanca R, Barban A, Passaro A, Pansini F, Bonaccorsi G, Mollica G, Fellin R. Simvastatin, transdermal patch, and oral estrogen-progestogen preparation in early-postmenopausal hypercholesterolemic women: a randomized, placebo-controlled clinical trial. *Metabolism.* 2002 Nov;51(11):1463-70
145. Sendag F, Karadadas N, Ozsener S, Bilgin O. Effects of sequential combined transdermal and oral hormone replacement therapies on serum lipid and lipoproteins in postmenopausal women. *Arch Gynecol Obstet.* 2002 Jan;266(1):38-43
146. Erenus M, Karakoc B, Gurler A. Comparison of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance. *Climacteric.* 2001 Sep;4(3):228-34
147. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. *Fertil Steril.* 2001 May;75(5):898-915

##### ***Progesterone treatment***

148. Houser SL, Aretz HT, Quist WC, Chang Y, Schreiber AD. Serum lipids and arterial plaque load are altered independently with high-dose progesterone in hypercholesterolemic male rabbits. *Cardiovasc Pathol.* 2000 Nov-Dec;9(6):317-22

**Atherosclerosis: the association with lower estrogen levels**

149. Bernini GP, Moretti A, Sgro M, Argenio GF, Barlascini CO, Cristofani R, Salvetti A. Influence of endogenous androgens on carotid wall in postmenopausal women. *Menopause.* 2001 Jan-Feb;8(1):43-50
150. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF, Davies JS. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. *J Clin Endocrinol Metab.* 2001 Sep;86(9):4261-7

**Atherosclerosis: the improvement with estrogen treatment**

151. Cagnacci A, Arangino S, Angiolucci M, Melis GB, Tarquini R, Renzi A, Volpe A. Different circulatory response to melatonin in postmenopausal women without and with hormone replacement therapy. *J Pineal Res.* 2000 Oct;29(3):152-8
152. de Kleijn MJ, Bots ML, Bak AA, Westendorp IC, Planellas J, Coelingh Bennink HJ, Witteman JC, Grobbee DE. Hormone replacement therapy in perimenopausal women and 2-year change of carotid intima-media thickness. *Maturitas.* 1999;32(3):195-204
153. Mullick AE, Walsh BA, Reiser KM, Rutledge JC. Chronic estradiol treatment attenuates stiffening, glycoxidation, and permeability in rat carotid arteries. *Am J Physiol Heart Circ Physiol.* 2001 Nov;281(5):H2204-10
154. Tremollieres FA, Cigagna F, Alquier C, Cauneille C, Pouilles J, Ribot C. Effect of hormone replacement therapy on age-related increase in carotid artery intima-media thickness in postmenopausal women. *Atherosclerosis.* 2000;153(1):81-8
155. Walsh BA, Mullick AE, Banka CE, Rutledge JC. 17beta-estradiol acts separately on the LDL particle and artery wall to reduce LDL accumulation. *J Lipid Res.* 2000 Jan;41(1):134-41
156. Walsh BA, Mullick AE, Walzem RL, Rutledge JC. 17beta-estradiol reduces tumor necrosis factor-alpha-mediated LDL accumulation in the artery wall. *J Lipid Res.* 1999 Mar;40(3):387-96
157. Jonas HA, Kronmal RA, Psaty BM, Manolio TA, Meilahn EN, Tell GS, Tracy RP, Robbins JA, Anton-Culver H. Current estrogen-progestin and estrogen replacement therapy in elderly women: association with carotid atherosclerosis. CHS Collaborative Research Group. *Cardiovascular Health Study; Ann Epidemiol.* 1996 Jul;6(4):314-23
158. Wagner JD. Rationale for hormone replacement therapy in atherosclerosis prevention. *J Reprod Med.* 2000 Mar;45(3 Suppl):245-58

**Arterial hypertension: the association with lower estrogen levels**

159. Harrison-Bernard LM, Schulman IH, Raji L. Postovariectomy hypertension is linked to increased renal AT1 receptor and salt sensitivity. *Hypertension.* 2003 Dec;42(6):1157-63
160. Clark JT, Chakraborty-Chatterjee M, Hamblin M, Wyss JM, Fentie IH. Estrogen depletion differentially affects blood pressure depending on age in Long-Evans rats. *Endocrine.* 2004 Nov;25(2):173-86
161. Peng N, Clark JT, Wei CC, Wyss JM. Estrogen depletion increases blood pressure and hypothalamic norepinephrine in middle-aged spontaneously hypertensive rats. *Hypertension.* 2003 May;41(5):1164-7

**Arterial hypertension: the improvement with estrogen treatment**

162. Mercurio G, Zoncu S, Piano D, Pilia I, Lao A, Melis GB, Cherchi A. Estradiol-17beta reduces blood pressure and restores the normal amplitude of the circadian blood pressure rhythm in postmenopausal hypertension. *Am J Hypertens.* 1998 Aug;11(8 Pt 1):909-13
163. Del Rio G, Velardo A, Zizzo G, Avogaro A, Cipolli C, Della Casa L, Marrama P, MacDonald IA. Effect of estradiol on the sympathoadrenal response to mental stress in normal men. *J Clin Endocrinol Metab.* 1994 Sep;79(3):836-40
164. Pang SC, Greendale GA, Cedars MI, Gambone JC, Lozano K, Eggena P, Judd HL. Long-term effects of transdermal estradiol with and without medroxyprogesterone acetate. *Fertil Steril.* 1993 Jan;59(1):76-82
165. Gerhard M, Walsh BW, Tawakol A, Haley EA, Creager SJ, Seely EW, Ganz P, Creager MA. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. *Circulation.* 1998 Sep 22;98(12):1158-63
166. Kornhauser C, Malacara JM, Garay ME, Perez-Luque EL. The effect of hormone replacement therapy on blood pressure and cardiovascular risk factors in menopausal women with moderate hypertension. *J Hum Hypertens.* 1997 Jul;11(7):405-11

167. Worboys S, Kotsopoulos D, Teede H, McGrath B, Davis SR. Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. *J Clin Endocrinol Metab.* 2001 Jan;86(1):158-61
168. Angerer P, Stork S, von Schacky C. Influence of 17beta-oestradiol on blood pressure of postmenopausal women at highvascular risk. *J Hypertens.* 2001 Dec;19(12):2135-42
169. Manhem K, Ahlm H, Dellborg M, Milsom I. Acute effects of transdermal estrogen in postmenopausal women with coronary artery disease. Using a clinically relevant estrogen dose and concurrent
170. antianginal therapy. *Cardiology.* 2000;94(2):86-90 (*"resting diastolic blood pressure was significantly decreased due to estrogen"*)
171. Seely EW, Walsh BW, Gerhard MD, Williams GH. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. *Hypertension.* 1999 May;33(5):1190-4.

#### **Cardiovascular disease: the association with lower estrogen levels**

172. Hanke H, Hanke S, Ickrath O, Lange K, Bruck B, Muck AO, Seeger H, Zwirner M, Voisard R, Haasis R, Hombach V. Estradiol concentrations in premenopausal women with coronary heart disease. *Coron Artery Dis.* 1997 Aug-Sep;8(8-9):511-5

#### **Coronary heart disease and other cardiac diseases: the improvement with estrogen treatment**

173. Cagnacci A, Arangino S, Angiolucci M, Melis GB, Tarquini R, Renzi A, Volpe A. Different circulatory response to melatonin in postmenopausal women without and with hormone replacement therapy. *J Pineal Res.* 2000 Oct;29(3):152-8
174. Paganini Hill A. The Leisure World Cohort Study. In *The Treatment of the Postmenopausal Women*-Lobo RA, Ed Paven Press – NY, 1994; p. 401: table 1
175. Delyani JA, Murohara T, Nossuli TO, Lefer AM. Protection from myocardial reperfusion injury by acute administration of 17 beta-estradiol. *Mol Cell Cardiol.* 1996 May;28(5):1001-8
176. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. *N Engl J Med.* 1991 Sep 12;325(11):756-62
177. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. *N Engl J Med.* 1996 Aug 15;335(7):453-61
178. Chen FP, Lee N, Wang CH, Cherng WJ, Soong YK. Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. *Fertil Steril.* 1998 Feb;69(2):267-73
179. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. *Ann Intern Med.* 2000 Dec 19;133(12):933-41
180. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. *JAMA.* 1998 Aug 19;280(7):605-13
181. Rosano GM, Webb CM, Chierchia S, Morgani GL, Gabraele M, Sarrel PM, de Ziegler D, Collins P. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. *J Am Coll Cardiol.* 2000 Dec;36(7):2154-9
182. Rouleau JR, Dagnault A, Simard D, Lavallee B, Belanger A, Blouin A, Kingma JG Jr. Effect of estrogen replacement therapy on distribution of myocardial blood flow in female anesthetized rabbits. *Jr Am J Physiol Heart Circ Physiol.* 2001;281(3):H1407-12
183. Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. *J Am Coll Cardiol.* 1992 Aug;20(2):452-7
184. Sudhir K, Chou TM, Mullen WL, Hausmann D, Collins P, Yock PG, Chatterjee K. Mechanisms of estrogen-induced vasodilation in canine coronary conductance and resistance arteries. *J Am Coll Cardiol.* 1995;26:807-14
185. Roque M, Heras M, Roig E, Masotti M, Rigol M, Betriu A, Balasch J, Sanz G. Short-term effects of transdermal estrogen replacement therapy on coronary vascular reactivity in postmenopausal women with angina pectoris and normal results on coronary angiograms. *J Am Coll Cardiol.* 1998 Jan;31(1):139-43
186. Albertsson PA, Emanuelsson H, Milsom I. Beneficial effect of treatment with transdermal estradiol-17-beta on exercise-induced angina and ST segment depression in syndrome X. *Int J Cardiol.* 1996 Apr 19;54(1):13-20

#### **Stroke and other cerebrovascular disorders: the association with lower estrogen levels**

187. Tsuda K, Nishio I. Hyperinsulinemia and estrogen-deficiency as risk factors for stroke in women. *Stroke*. 2004 Jun;35(6):e134
188. Pines A, Bornstein NM, Shapira I. Menopause and ischaemic stroke: basic, clinical and epidemiological considerations. The role of hormone replacement. *Hum Reprod Update*. 2002 Mar-Apr;8(2):161-8

#### **Stroke: the improvement with estrogen treatment**

189. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. *Arterioscler Thromb Vasc Biol*. 1997 Nov;17(11):3071-8
190. Frohlich M, Schunkert H, Hense HW, Tropitzsch A, Hendricks P, Doring A, Riegger GA, Koenig W. Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women. *Br J Haematol*. 1998 Mar;100(3):577-81
191. Simpkins JW, Rajakumar G, Zhang YQ, Simpkins CE, Greenwald D, Yu CJ, Bodor N, Day AL. Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. *J Neurosurg*. 1997 Nov;87(5):724-30
192. Rusa R, Alkayed NJ, Crain BJ, Traystman RJ, Kimes AS, London ED, Klaus JA, Hurn PD. 17beta-estradiol reduces stroke injury in estrogen-deficient female animals. *Stroke*. 1999 Aug;30(8):1665-70

#### **Obesity: the association with lower estrogen levels**

193. Tchernof A, Poehlman ET, Despres JP. Body fat distribution, the menopause transition, and hormone replacement therapy. *Diabetes Metab*. 2000 Feb;26(1):12-20
194. Carr MC. The emergence of the metabolic syndrome with menopause. *J Clin Endocrinol Metab*. 2003 Jun;88(6):2404-11

#### **Obesity: the improvement with estrogen treatment**

195. Sorensen MB, Rosenfalck AM, Hojgaard L, Ottesen B. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. *Obes Res*. 2001 Oct;9(10):622-6
196. Tofovic SP, Dubey RK, Jackson EK. 2-Hydroxyestradiol attenuates the development of obesity, the metabolic syndrome, and vascular and renal dysfunction in obese ZSF1 rats. *J Pharmacol Exp Ther*. 2001 Dec;299(3):973-7
197. Chmouliovsky L, Habicht F, James RW, Lehmann T, Campana A, Golay A. Beneficial effect of hormone replacement therapy on weight loss in obese menopausal women. *Maturitas*. 1999 Aug 16;32(3):147-53
198. Davis SR, Walker KZ, Strauss BJ. Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. *Menopause*. 2000 Nov-Dec;7(6):395-401

#### **Diabetes: the association with lower estrogen levels**

199. Garris DR. The effects of estradiol and progesterone on reproductive tract atrophy and tissue adrenergic indices in diabetic C57BL/KsJ mice. *Proc Soc Exp Biol Med*. 1990 Jan;193(1):39-45
200. \* Gorodeski GI. Impact of the menopause on the epidemiology and risk factors of coronary artery heart disease in women. *Exp Gerontol*. 1994 May-Aug;29(3-4):357-75
201. [Kahn SE](#), [Andrikopoulos S](#), [Verchere CB](#), [Wang E](#), [Hull RL](#), [Vidal J](#). Oophorectomy promotes islet amyloid formation in a transgenic mouse model of Type II diabetes. *Diabetologia*. 2000 Oct;43(10):1309-12

#### **Diabetes: the improvement with estrogen treatment**

202. [Mattsson LA](#), [Hahn L](#), [Marin P](#), [Lapidus L](#), [Holm G](#), [Bengtsson BA](#), [Bjorntorp P](#). Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. *J Clin Endocrinol Metab*. 1997 Feb;82(2):638-43
203. Rossi R, Origliani G, Modena MG. Transdermal 17-beta-estradiol and risk of developing type 2 diabetes in a population of healthy, nonobese postmenopausal women. *Diabetes Care*. 2004 Mar;27(3):645-9
204. Raudaskoski T, Tomas C, Laatikainen T. Insulin sensitivity during postmenopausal hormone replacement with transdermal estradiol and intrauterine levonorgestrel. *Acta Obstet Gynecol Scand* 1999 Jul;78(6):540-5
205. Cucinelli F, Paparella P, Soranna L, Barini A, Cinque B, Mancuso S, Lanzone A. Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in

- postmenopausal women: relation to their insulinemic secretion. *Eur J Endocrinol* 1999 Mar;140(3):215-23
206. Cagnacci A, Tuveri F, Cirillo R, Setteneri AM, Melis GB, Volpe A. The effect of transdermal 17-beta-estradiol on glucose metabolism of postmenopausal women is evident during the oral but not the intravenous glucose administration. *Maturitas* 1997 Dec 15;28(2):163-7
207. O'Sullivan AJ, Ho KK. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. *J Clin Endocrinol Metab* 1995 Jun;80(6):1783-8
208. Cagnacci A, Soldani R, Carriero PL, Paoletti AM, Fioretti P, Melis GB. Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women. *J Clin Endocrinol Metab* 1992 Jun;74(6):1396-400
209. Spencer CP, Godsland IF, Cooper AJ, Ross D, Whitehead MI, Stevenson JC. Effects of oral and transdermal 17-beta-estradiol with cyclical oralnorethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. *Metabolism* 2000 Jun;49(6):742-7
210. Karjalainen A, Paassilta M, Heikkinen J, Backstrom AC, Savolainen M, Kesaniemi YA. Effects of peroral and transdermal oestrogen replacement therapy on glucose and insulin metabolism. *Clin Endocrinol (Oxf)*. 2001 Feb;54(2):165-73
211. Cucinelli F, Paparella P, Soranna L, Barini A, Cinque B, Mancuso S, Lanzone A. Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion. *Eur J Endocrinol*. 1999 Mar;140(3):215-23
212. Darko DA, Dornhorst A, Kennedy G, Mandeno RC, Seed M. Glycaemic control and plasma lipoproteins in menopausal women with Type 2 diabetes treated with oral and transdermal combined hormone replacement therapy. *Diabetes Res Clin Pract* 2001 Dec;54(3):157-64

#### **Rheumatism: the association with lower estrogen levels**

213. Jochems C, Islander U, Erlandsson M, Verdrengh M, Ohlsson C, Carlsten H. Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation. *Arthritis Res Ther*. 2005;7(4):R837-43
214. Yoneda T, Ishimaru N, Arakaki R, Kobayashi M, Izawa T, Moriyama K, Hayashi Y. Estrogen deficiency accelerates murine autoimmune arthritis associated with receptor activator of nuclear factor-kappa B ligand-mediated osteoclastogenesis. *Endocrinology*. 2004 May;145(5):2384-91

#### **Rheumatism: the improvement with estrogen treatment**

215. Doran MF, Crowson CS, O'Fallon WM, Gabriel SE. The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: a population based study. *J Rheumatol*. 2004 Feb;31(2):207-13
216. D'Elia HF, Larsen A, Mattsson LA, Waltbrand E, Kvist G, Mellstrom D, Saxne T, Ohlsson C, Nordborg E, Carlsten H. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. *J Rheumatol*. 2003 Jul;30(7):1456-63
217. Hall GM, Daniels M, Huskisson EC, Spector TD. A randomised controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. *Ann Rheum Dis*. 1994 Feb;53(2):112-6
218. MacDonald AG, Murphy EA, Capell HA, Bankowska UZ, Ralston SH. Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study. *Ann Rheum Dis*. 1994 Jan;53(1):54-7
219. Vandenbroucke JP, Wittman JC, Valkenburg HA, Boersma JW, Cats A, Festen JJ, Hartman AP, Huber-Bruning O, Rasker JJ, Weber J. Noncontraceptive hormones and rheumatoid arthritis in perimenopausal and postmenopausal women. *JAMA*. 1986 Mar 14;255(10):1299-303

#### **Osteoporosis: the association with lower estrogen levels**

##### **Estrogen levels**

220. Richelson LS, Wahner HW, Melton LJ 3rd, Riggs BL. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. *N Engl J Med*. 1984 Nov 15; 311(20): 12273-5
221. Bourdel A, Mahoudeau JA, Guaydier-Souquieres G, Leymarie P, Sabatier JP, Loyau G. Gonadal function in primary apparent male osteoporosis. 12 cases. *Presse Med*. 1989 Oct 21;18(34):1691-4
222. Khosla S, Riggs BL, Robb RA, Camp JJ, Achenbach SJ, Oberg AL, Rouleau PA, Melton LJ 3rd. Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in women. *J Clin Endocrinol Metab*. 2005 Sep;90(9):5096-103
223. Tremollieres FA, Pouilles JM, Ribot C. Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women *Osteoporos Int*. 2001;12(5):385-90
224. Huang JS, Wilkie SJ, Sullivan MP, Grinspoon S. Reduced bone density in androgen-deficient women with acquired immune deficiency syndrome wasting. *J Clin Endocrinol Metab*. 2001 Aug;86(8):3533-9

### ***Estrogens and androgen levels***

225. Deutsch S, Benjamin F, Seltzer V, Tafreshi M, Kocheril G, Frank A. The correlation of serum estrogens and androgens with bone density in the late postmenopause. *Int J Gynaecol Obstet.* 1987 Jun;25(3):217-22
226. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. *J Bone Miner Res.* 2000 Aug;15(8):1526-36
227. Lau EM, Suriwongpaisal P, Lee JK, Das De S, Festin MR, Saw SM, Khir A, Torralba T, Sham A, Sambrook P. Risk factors for hip fracture in Asian men and women: the Asian osteoporosis study. *J Bone Miner Res.* 2001 Mar;16(3):572-80
228. van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. *J Clin Endocrinol Metab.* 2000 Sep;85(9):3276-82

### **Osteoporosis: the improvement with**

#### ***Estrogen and progestin treatment***

229. Sorensen MB, Rosenfalck AM, Hojgaard L, Ottesen B. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. *Obes Res.* 2001 Oct;9(10):622-6
230. Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. *Lancet.* 1981 Feb 28;1(8218):459-61.
231. Christiansen C, Christensen MS, McNair P, Hagen C, Stocklund KE, Transbol I. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. *Eur J Clin Invest.* 1980 Aug;10(4):273-9.
232. Bagur A, Wittich A, Ghiringhelli G, Vega E, Mautalen C. Hormone replacement therapy increases trabecular and cortical bone density in osteoporotic women. *Medicina (B Aires).* 1996;56(3):247-51
233. Tiras MB, Noyan V, Yildiz A, Biberoglu K. Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate. *Climacteric.* 2000 Jun;3(2):92-101
234. Ringe JD, Meiss F. The avoidance of early postmenopausal bone substance losses by transdermal estrogen substitution. *Dtsch Med Wochenschr.* 1993 May 28;118(21):769-74
235. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, Judd HL, Caplan RH, Riggs BL. Treatment of postmenopausal osteoporosis with transdermal estrogen. *Ann Intern Med.* 1992 Jul 1;117(1):1-9

#### ***Transdermal, intranasal or implant estradiol treatment***

236. Riis BJ, Thomsen K, Strom V, Christiansen C. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. *Am J Obstet Gynecol.* 1987 Jan;156(1):61-5
237. Nielsen TF, Ravn P, Bagger YZ, Warming L, Christiansen C. Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study. *Osteoporos Int.* 2004 Feb;15(2):168-74
238. Notelovitz M, John VA, Good WR. Effectiveness of Alora estradiol matrix transdermal delivery system in improving lumbar bone mineral density in healthy, postmenopausal women. *Menopause.* 2002 Sep-Oct;9(5):343-53
239. Arrenbrecht S, Boermans AJ. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial. *Osteoporos Int.* 2002;13(2):176-83.
240. Castelo-Branco C, Vicente JJ, Figueras F, Sanjuan A, Martinez de Osaba MJ, Casals E, Pons F, Balasch J, Vanrell JA. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. *Maturitas.* 2000 Feb
241. Cooper C, Stakkestad JA, Radawicki S, Hardy P, Pilate C, Dain MP, Delmas PD. Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. *Osteoporos Int.* 1999;9(4):358-66
242. Evans SF, Davie MW. Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages. *Clin Endocrinol (Oxf).* 1996 Jan;44(1):79-84
243. Ribot C, Tremollieres F, Pouilles JM, Louvet JP, Peyron R. Preventive effects of transdermal administration of 17 beta-estradiol on postmenopausal bone loss: a 2-year prospective study. *Gynecol Endocrinol.* 1989 Dec;3(4):259-67

244. Holland EF, Leather AT, Studd JW. Increase in bone mass of older postmenopausal women with low mineral bone density after one year of percutaneous oestradiol implants. *Br J Obstet Gynaecol.* 1995 Mar;102(3):238-42

#### **Progestin (including progesterone) treatment**

245. Liu JH, Muse KN. The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. *Am J Obstet Gynecol.* 2005 Apr;192(4):1316-23
246. Lydeking-Olsen E, Beck-Jensen JE, Setchell KD, Holm-Jensen T. Soy milk or progesterone for prevention of bone loss--a 2 year randomized, placebo-controlled trial. *Eur J Nutr.* 2004 Aug;43(4):246-57
247. Grey A, Cundy T, Evans M, Reid I. Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women. *Clin Endocrinol (Oxf).* 1996 Mar;44(3):293-6
248. Lee JR. Osteoporosis reversal with transdermal progesterone. *Lancet.* 1990 Nov 24;336(8726):1327
249. Lee JR. Is natural progesterone the missing link in osteoporosis prevention and treatment? *Med Hypotheses.* 1991 Aug;35(4):316-8
250. Barengolts EI, Gajardo HF, Rosol TJ, D'Anza JJ, Pena M, Botsis J, Kukreja SC. Effects of progesterone on postovariectomy bone loss in aged rats. *J Bone Miner Res.* 1990 Nov;5(11):1143-7

#### **Hip fractures: the association with lower estrogen levels**

251. Chapurlat RD, Garnero P, Breart G, Meunier PJ, Delmas PD. Serum estradiol and sex hormone-binding globulin and the risk of hip fracture in elderly women: the EPIDOS study. *J Bone Miner Res.* 2000 Sep;15(9):1835-41
252. Yates J, Barrett-Connor E, Barlas S, Chen YT, Miller PD, Siris ES. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. *Obstet Gynecol.* 2004 Mar;103(3):440-6 (5 years after stopping estrogen use => loss of protection against hip fractures)

#### **Hip fractures: the prevention with estrogen-progestin use**

253. Michaelsson K, Baron JA, Farahmand BY, Persson I, Ljunghall S. Oral-contraceptive use and risk of hip fracture: a case-control study. *Lancet.* 1999 May 1;353(9163):1481-4 (-50 % less hip fractures)
254. Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. *N Engl J Med.* 1987 Nov 5;317(19):1169-74
255. Kiel DP, Baron JA, Anderson JJ, Hannan MT, Felson DT. Smoking eliminates the protective effect of oral estrogens on the risk for hip fracture among women. *Ann Intern Med.* 1992 May 1;116(9):716-21
256. Yates J, Barrett-Connor E, Barlas S, Chen YT, Miller PD, Siris ES. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. *Obstet Gynecol.* 2004 Mar;103(3):440-6

#### **Cancer: the association with**

##### **Lower estrogen levels**

257. Holmberg L, Norden T, Lindgren A, Wide L, Degerman M, Adami HO. Pre-operative oestradiol levels - relation to survival in breast cancer. *Eur J Surg Oncol* 2001 Mar;27(2):152-6
258. MacMahon B, Cole P, Brown JB, Aoki K, Lin TM, Morgan RW, Woo NC. Urine oestrogen profiles of Asian and North American women. *Int J Cancer.* 1974 Aug 15;14(2):161-7
259. MacMahon B, Cole P, Brown JB, Aoki K, Lin TM, Morgan RW, Woo N. Oestrogen profiles of Asian and North American women. *Lancet.* 1971 Oct 23;2(7730):900-2
260. Ursin G, Wilson M, Henderson BE, Kolonel LN, Monroe K, Lee HP, Seow A, Yu MC, Stanczyk FZ, Gentschein E Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women? *Cancer Res.* 2001 Apr 15;61(8):3326-9
261. Ursin G, London S, Stanczyk FZ, Gentschein E, Paganini-Hill A, Ross RK, Pike MC. Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. *J Natl Cancer Inst* 1999 Jun 16;91(12):1067-72
262. Lemon HM. Pathophysiologic considerations in the treatment of menopausal patients withoestrogens; the role of oestriol in the prevention of mammary carcinoma. *Acta Endocrinol Suppl (Copenh)* 1980;233:17-27
263. Vorherr H, Messer RH. Breast cancer: potentially predisposing and protecting factors. Role of pregnancy, lactation, and endocrine status. *Am J Obstet Gynecol* 1978 Feb 1;130(3):335-58

##### **Lower progesterone levels**

264. Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. *Am J Epidemiol* 1981 Aug;114(2):209-17
265. Adami HO, Bergstrom R, Holmberg L, Klareskog L, Persson I, Ponten J. The effect of female sex hormones on cancer survival. A register-based study in patients younger than 20 years at diagnosis. *JAMA*. 1990 Apr 25;263(16):2189-93
266. Adami HO, Holmberg L, Persson I. Survival and age at diagnosis in breast cancer. *N Engl J Med*. 1987 ; 316(12): 750-2
267. Mohr PE, Wang DY, Gregory WM, Richards MA, Fentiman IS. Serum progesterone and prognosis in operable breast cancer. *Br J Cancer*. 1996 Jun;73(12):1552-5
268. Badwe RA, Wang DY, Gregory WM, Fentiman IS, Chaudary MA, Smith P, Richards MA, Rubens RD. Serum progesterone at the time of surgery and survival in women with premenopausal operable breast cancer. *Eur J Cancer*. 1994;30A(4):445-8

#### **Cancer: protection with estrogen treatment?**

269. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. *Arch Intern Med* 1991; 151:75

#### **Studies with reduced breast cancer risk in women with the intake of progesterone or one of its' derivatives**

270. Plu-Bureau G, Le MG, Thalabard JC, Sitruk-Ware R, Mauvais-Jarvis P. Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease. *Cancer Detect Prev* 1999;23(4):290-6
271. Lauritzen C et al. Risks of endometrial and mammary cancer morbidity and mortality in long-term estrogen treatment. In *The Climacteric -An Update*, ed by van Herendael H & B, Riphagen FE, Goessens L, van der Pars H Lancaster, England, MTP Press Ltd 1984; 207
272. Peters GN, Fodera T, Sabol J, Jones S, Euhus D. Estrogen replacement therapy after breast cancer: a 12-year follow-up. *Ann Surg Oncol* 2001 Dec;8(10):828-32
273. Gambrell RD Jr. Hormones in the etiology and prevention of breast and endometrial cancer. *South Med J*. 1984 Dec; 77(12): 1509-15.
274. Gambrell RD Jr, Maier RC, Sanders BI. Decreased incidence of breast cancer in postmenopausal estrogen progestogen users. *Obstet Gynecol* 1983 Oct;62(4):435-43
275. Wingo PA, Layde PM, Lee NC, Rubin G, Ory HW. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. *JAMA*. 1987 Jan 9; 257(2): 209-15
276. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. *Obstet Gynecol*. 1979; 54: 74-9
277. Davelaar EM, Gerretsen G, Relyveld J.. No increase in the incidence of breast carcinoma with subcutaneous administration of estradiol *Ned Tijdsch Geneesk*. 1991 Apr 6 ; 135(14): 613-5
278. Rosenberg L, Miller DR, Kaufman DW, Helmrich SP, Stolley PD, Schottenfeld D, Shapiro S. Breast cancer and oral contraceptive use. *Am J Epidemiol* 1984 Feb;119(2):167-76
279. Kaufman DW, Miller DR, Rosenberg L, Helmrich SP, Stolley P, Schottenfeld D, Shapiro S. Noncontraceptive estrogen use and the risk of breast cancer. *JAMA* 1984 Jul 6;252(1):63-7
280. Hammond CB, Jelovsek FR, Lee KI, WT, Parker. Effects of long term estrogen replacement therapy. II - Neoplasia. *Am J Obstet Gynecol*. 1979; 133: 537 (*Reduced aggressivity of breast cancer if HRT before*)

#### **Studies where estrogen therapy increased the lifespan in women with familial risk of breast cancer**

281. Sellers, TA, Mink, PJ, Cerhan, JR, g W, Anderson KE, Kushi LH, Folsom AR. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. *Ann Intern Med* 1997; 127:973

#### **Studies of estrogen treatment of women with previous breast cancer: increased longevity/survival and reduced recurrence**

282. Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. *Am J Surg*. 1993 Mar;165(3):372-5
283. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence & mortality. *J Natl Cancer Inst*. 2001;93(10):754-62

### **Studies where the use of female hormone replacement therapy reduced the recurrence of breast cancer**

284. Dew JE, Wren BG, Eden JA. Tamoxifen, hormone receptors & hormone replacement therapy in women previously treated for breast cancer: a cohort study. *Climacteric*. 2002;5(2):151-5
285. Dew J, Eden J, Beller E, Magarey C, Schwartz P, Crea P, Wren B. A cohort study of hormone replacement therapy given to women previously treated for breast cancer. *Climacteric*.1998;1(2):137-42
286. Durna EM, Wren BG, Heller GZ, Leader LR, Sjoblom P, Eden JA. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. *Med J Aust*. 2002 Oct 7;177(7):347-51
287. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, Berkelman RL. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. *JAMA*. 1991 Apr 17;265(15):1985-90
288. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE. Postmenopausal hormone therapy and mortality. *N Engl J Med*. 1997; 336:1769-75
289. Mohammed SN, Smith P, Hodgson SV, Fentiman IS, Miles DW, Barnes DM, Millis RR, Rubens RD Family history and survival in premenopausal breast cancer. *Br J Cancer*. 1998 Jun;77(12):2252-6
290. Gajdos C, Tartter PI, Babinszki A. Breast cancer diagnosed during hormone replacement therapy. *Obstet Gynecol*. 2000 Apr;95(4):513-8
291. Holli K, Isola J, Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. *J Clin Oncol*. 1998 Sep;16(9):3115-20
292. Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I. Prognostic characteristics in breast cancers after hormone replacement therapy. *Breast Cancer Res Treat*. 1996;38(3):325-34
293. Meurer LN, Lena S. Cancer recurrence and mortality in women using hormone replacement therapy: meta-analysis. *J Fam Pract*. 2002 Dec;51(12):1056-62
294. Ursin G, Tseng CC, Paganini-Hill A, Enger S, Wan PC, Formenti S, Pike MC, Ross RK. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? *Arch 1: J Clin Oncol* 2002 Feb 1;20(3):699-706
295. Nanda K, Bastian LA, Schulz K. Hormone replacement therapy and the risk of death from breast cancer: a systematic review. *Am J Obstet Gynecol*. 2002 Feb; 186 (2):325-34
296. Willis DB, Calle EE, Miracle-McMahill HL, Heath CW Jr. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. *Cancer Causes Control*. 1996 Jul;7(4):449-57
297. Schairer C, Gail M, Byrne C, Rosenberg PS, Sturgeon SR, Brinton LA, Hoover RN. Estrogen replacement therapy and breast cancer survival in a large screening study. *J Natl Cancer Inst*. 1999 Feb 3;91(3):264-70
298. Ettinger B, Friedman, GD, Bush, T, Quesenberry CP Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. *Obstet Gynecol*. 1996 Jan;87(1):6-12
- 1140 Jernstrom H, Frenander J, Ferno M, Olsson H. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. *Br J Cancer*. 1999 Jul;80(9):1453-8
299. Hunt K, Vessey M, McPherson K. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. *Br J Obstet Gynaecol*. 1987; 94: 620-35
300. Plu-Bureau G, Le MG, Sitruk-Ware R, Thalabard JC, Mauvais-Jarvis P. Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease. *Br J Cancer*. 1994 Aug;70(2):270-7
301. Lundgren S, Lonning PE. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer -II. A differential effect of megestrol acetate and medroxyprogesterone acetate on serum estrone sulfate and sex hormone binding globulin. *J Steroid Biochem*. 1990 Jun ; 36(1-2): 105-9

### **Longevity: the association with higher progesterone levels**

302. Mohr PE, Wang DY, Gregory WM, Richards MA, Fentiman IS. Serum progesterone and prognosis in operable breast cancer. *Br J Cancer*. 1996 Jun;73(12):1552-5

### **Longevity: the improvement with estrogen treatment**

303. Petitti DB, Perlman JA, Sidney S. Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. *Obstet Gynecol*. 1987 Sep;70(3 Pt 1):289-93
304. Natrajan PK, Soumakis K, Gambrell RD Jr. Estrogen replacement therapy in women with previous breast cancer. *Am J Obstet Gynecol*. 1999;181(2):288-95
305. DiSaia PJ, Brewster WR, Ziogas A, Anton-Culver H. Breast cancer survival and hormone replacement therapy: a cohort analysis. *Am J Clin Oncol*. 2000 Dec;23(6):541-5

306. Jernstrom H, Frenander J, Ferno M, Olsson H. Hormone replacement therapy before breast cancer diagnosis sign. reduces the overall death rate compared with never-use among 984 breast cancer patients. *Br J Cancer*. 1999;80(9):1453-8

## **V. References on estrogen and progesterone treatment**

### **Corrective estrogen and progestogen treatments**

#### **Estrogen treatments**

307. Baker VL. Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery. *Obstet Gynecol Clin North Am*. 1994 Jun;21(2):271-97
308. Kuhl H. Pharmacokinetics of oestrogens and progestogens. *Maturitas*. 1990 Sep;12(3):171-97

#### ***Oral estradiol, conjugated estrogens***

309. Schindler AE, Bolt HM, Zwirner M, Hochlehnert G, Goser R. Comparative pharmacokinetics of oestradiol, oestrone, oestrone sulfate and "conjugated oestrogens" after oral administration. *Arzneimittelforschung*. 1982;32(7):787-91 Vree TB, Timmer CJ. Enterohepatic cycling and pharmacokinetics of oestradiol. *J Pharm Pharmacol*. 1998 Aug;50(8):857-64

#### ***Transdermal estradiol***

310. Jarvinen A, Granander M, Nykanen S, Laine T, Geurts P, Viitanen A. Steady-state pharmacokinetics of estradiol gel in post-menopausal women: effects of application area and washing. *Br J Obstet Gynaecol*. 1997 Nov;104 Suppl 16:14-8
311. Shulman LP, Harari D. Low-dose transdermal estradiol for symptomatic perimenopause. *Menopause*. 2004 Jan-Feb;11(1):34-9
312. Haensch CA, Freimark E, Jorg J. Transdermal absorption of estradiol in normal subjects and in patients with peripheral neuropathies. *Clin Auton Res*. 2003 Dec;13(6):450-2
313. Schmolling J, Kusche J, van der Ven H, Schander K. Bioavailability of 17 beta-estradiol after transdermal administration--dependence on the patch system. *Zentralbl Gynakol*. 1998;120(3):121-5
314. Brennan JJ, Lu Z, Whitman M, Stafiniak P, van der Hoop RG. Serum concentrations of 17beta-estradiol and estrone after multiple-dose administration of percutaneous estradiol gel in symptomatic menopausal women. *Ther Drug Monit*. 2001 Apr;23(2):134-8
315. Paoletti AM, Pilia I, Nannipieri F, Bigini C, Melis GB. Comparison of pharmacokinetic profiles of a 17 beta-estradiol gel 0.6 mg/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state. *Maturitas*. 2001 Dec 14;40(3):203-9.
316. Runnebaum B, Salbach B, von Holst T. Oral or transdermal estrogen substitution therapy in climacteric? *Geburtshilfe Frauenheilkd*. 1994 Mar;54(3):119-30
317. Scott RT Jr, Ross B, Anderson C, Archer DF. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. *Obstet Gynecol*. 1991 May;77(5):758-64.
318. Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 beta-estradiol: comparison with conventional oral estrogens used for hormone replacement. *Am J Obstet Gynecol*. 1985 Aug 15;152(8):1099-106

#### ***Estradiol implant***

319. del Carmen Cravioto M, Larrea F, Delgado NE, Escobar AR, Diaz-Sanchez V, Dominguez J, de Leon RP. Pharmacokinetics and pharmacodynamics of 25-mg estradiol implants in postmenopausal Mexican women. *Menopause*. 2001 Sep-Oct;8(5):353-60

#### ***Vaginal estradiol***

320. Englund DE, Victor A, Johansson ED. Pharmacokinetics and pharmacodynamic effects of vaginal oestradiol administration from silastic rings in post-menopausal women. *Maturitas*. 1981 Aug;3(2):125-33
321. Weisberg E, Ayton R, Darling G, Farrell E, Murkies A, O'Neill S, Kirkegard Y, Fraser IS. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. *Climacteric*. 2005 Mar;8(1):83-92

### **Transdermal estradiol treatment: dosage, site of application**

322. Taggart W, Dandekar K, Ellman H, Notelovitz M. The effect of site of application on the transcutaneous absorption of 17-beta estradiol from a transdermal delivery system (Climara). *Menopause*. 2000 Sep-Oct;7(5):364-9.
323. Jarvinen A, Granander M, Laine T, Viitanen A. Effect of dose on the absorption of estradiol from a transdermal gel. *Maturitas*. 2000 Apr 28;35(1):51-6.

### **Progesterone treatments**

324. Stanczyk FZ. All progestins are not created equal. *Steroids*. 2003 Nov;68(10-13):879-90
325. Kuhl H. Pharmacokinetics of oestrogens and progestogens. *Maturitas*. 1990 Sep;12(3):171-97

### **Oral progesterone**

326. Andreen L, Spigset O, Andersson A, Nyberg S, Backstrom T. Pharmacokinetics of progesterone and its metabolites allopregnanolone and pregnanolone after oral administration of low-dose progesterone. *Maturitas*. 2006; First published online Jan 4
327. Stanczyk FZ. Pharmacokinetics of progesterone administered by the oral and parenteral routes. *J Reprod Med*. 1999 Feb;44(2 Suppl):141-7
328. Fitzpatrick LA, Good A. Micronized progesterone: clinical indications and comparison with current treatments. *Fertil Steril*. 1999 Sep;72(3):389-97
329. Mircioiu C, Perju A, Griu E, Calin G, Neagu A, Enachescu D, Miron DS, Simon JA, Robinson DE, Andrews MC, Hildebrand JR 3rd, Rocci ML Jr, Blake RE, Hodgen GD. The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. *Fertil Steril*. 1993 Jul;60(1):26-33
330. Sitruk-Ware R, Bricaire C, De Lignieres B, Yaneva H, Mauvais-Jarvis P. Oral micronized progesterone. Bioavailability pharmacokinetics, pharmacological and therapeutic implications - a review. *Contraception*. 1987 Oct;36(4):373-402

### **Oral dydrogesterone**

331. Winkler UH, Lauck US, Ebert C, Schindler AE. The effect of cyclic administration of progestagens on blood coagulation factors. *Zentralbl Gynakol*. 1998;120(1):32-7 (*Dydrogesterone treatment did not change parameters of hemostasis and fibrinolysis, esp. e no activation of the coagulation system*)
332. Sipowicz I, Chomczyk I. The efficacy of dydrogesterone in the treatment of menstrual cycle disorders in girls. *Ginekol Pol*. 1998 Oct;69(10):767-70. Polish.
333. Sampson GA, Heathcote PR, Wordsworth J, Prescott P, Hodgson A. Premenstrual syndrome. A double-blind cross-over study of treatment with dydrogesterone and placebo. *Br J Psychiatry*. 1988 Aug;153:232-5

### **Oral norethisterone**

334. Zalanyi S, Landgren BM, Johannisson E. Pharmacokinetics, pharmacodynamic and endometrial effects of a single dose of 200 mg norethisterone enanthate. *Contraception*. 1984 Sep;30(3):225-37

### **Vaginal progesterone**

335. Mircioiu C, Perju A, Neagu A, Griu E, Calin G, Miron DS. Pharmacokinetics of progesterone in postmenopausal women: 1. Pharmacokinetics following intravaginal administration. *Eur J Drug Metab Pharmacokinet*. 1998 Jul-Sep;23(3):391-6
336. von Eye Corleta H, Capp E, Ferreira MB. Pharmacokinetics of natural progesterone vaginal suppository. *Gynecol Obstet Invest*. 2004;58(2):105-8
337. Cicinelli E, Borraccino V, Petrucci D, Mazzotta N, Cerundolo ML, Schonauer LM. Pharmacokinetics and endometrial effects of the vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. *Fertil Steril*. 1996 Apr;65(4):860-2

### **Sublingual/ buccal progesterone**

338. Stanczyk FZ. Pharmacokinetics of progesterone administered by the oral and parenteral routes. *J Reprod Med*. 1999 Feb;44(2 Suppl):141-7
339. Wren BG, Day RO, McLachlan AJ, Williams KM. Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women. *Climacteric*. 2003 Jun;6(2):104-11

### ***Transdermal progesterone***

- 340. Pharmacokinetics of progesterone in postmenopausal women: 2. Pharmacokinetics following percutaneous administration. *Eur J Drug Metab Pharmacokinet.* 1998 Jul-Sep;23(3):397-402
- 341. Vashisht A, Wadsworth F, Carey A, Carey B, Studd J. A study to look at hormonal absorption of progesterone cream used in conjunction with transdermal estrogen. *Gynecol Endocrinol.* 2005 Aug;21(2):101-5
- 342. Carey BJ, Carey AH, Patel S, Carter G, Studd JW. A study to evaluate serum and urinary hormone levels following short and long term administration of two regimens of progesterone cream in postmenopausal women. *BJOG.* 2000 Jun;107(6):722-6
- 343. Stanczyk FZ. Pharmacokinetics of progesterone administered by the oral and parenteral routes. *J Reprod Med.* 1999 Feb;44(2 Suppl):141-7

### **Female hormone treatment: interferences**

#### ***Estrogen treatment: interferences***

- 344. O'Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. *J Clin Pharmacol.* 1995 Sep;35(9 Suppl):18S-24S
- 345. Bispink L, Brandle W, Lindner C, Bettendorf G. Preclinical hypothyroidism and disorders of ovarian function. *Geburtshilfe Frauenheilkd.* 1989 Oct;49(10):881-8.
- 346. Radwanska E, Berger GS, Hammond J. Luteal deficiency among women with normal menstrual cycles, requesting reversal of tubal sterilization. *Obstet Gynecol.* 1979 Aug;54(2):189-92

### **Female hormone replacement: follow-up**

- 347. Wren BG, McFarland K, Edwards L, O'Shea P, Sufi S, Gross B, Eden JA. Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women. *Climacteric.* 2000 Sep;3(3):155-60
- 348. Bolaji II, Tallon DF, O'Dwyer E, Fottrell PF. Assessment of bioavailability of oral micronized progesterone using a salivary progesterone enzymeimmunoassay. *Gynecol Endocrinol.* 1993 Jun;7(2):101-10.
- 349. Worthman CM, Stallings JF, Hofman LF. Sensitive salivary estradiol assay for monitoring ovarian function. *Clin Chem.* 1990 Oct;36(10):1769-73